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Abstract
The lipid mediator sphingosine-1-phosphate (S1P) is involved in many 
growth-related processes including migration, angiogenesis and survival. S1P 
exerts its effects through the G protein-coupled receptors named S IP 1.5. S IP 1, 
the first receptor to be identified is associated with regulation of cytoskeletal 
dynamics by differential regulation of small G proteins such as Rac, Rho and 
Cdc42 which are crucial mediators of migration. S1P-mediated signalling has 
long been associated with cell survival but the mechanisms are not completely 
understood.
However, using the model system of Chinese hamster lung fibroblasts 
(CGL39) stably expressing the S IP 1 receptor, S1P-mediated Rac and Cdc42 
activation was not detected. S IP 2 which inhibits Rac activation was not 
detected and the selective inhibitor which binds all S1P receptors except S IP 2 
did not rescue this effect.
Using CCL39mycS1Pi cells it was demonstrated that the presence of 
this receptor has a protective effect against apoptosis caused by the removal of 
trophic factors. Control CCL39 cells showed increased levels of apoptotic 
initiator protein, Bim and the executioner protein active caspase-3. This effect 
is not ERK-dependent nor is it dependent on total levels of the pro-apoptotic 
mediator Bim. This also occurred in the absence of agonist or endogenous S1P 
production.
Inhibition of S1Pi-mediated signalling pathways such as PI 3-kinase/PKB 
pathway and PKC completely attenuated this protective effect. Furthermore, 
blocking protein synthesis by emetine treatment is also reversed the protective '
which strongly suggests that S IP 1 receptor signalling is the driving force behind 
the up-regulation of one or more anti-apoptotic proteins which bind and 
sequester Bim. Understanding the mechanisms by which control growth 
patterns are regulated is important in the development of new drugs to combat 
growth-related diseases such as cancer.
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Chapter 1 
Introduction
1.1 G Protein Coupled Receptors
G protein coupled receptors (GPCRs) comprise the largest and most 
functionally diverse superfamily of transmembrane proteins involved in cell 
signalling. It is estimated that the human genome contains approximately 
eight hundred GPCR sequences [1]. GPCRs respond to a diverse range of 
stimuli such as lipids, light, odorants, peptide hormones, neurotransmitters 
and chemokines each activating specific intracellular signalling cascades via 
interaction with heterotrimeric G proteins [2]. GPCRs are involved in many 
physiological and pathophysiological processes and thereby constitute major 
therapeutic targets. In humans there are approximately 367 receptors for 
which the endogenous ligand is known, but there remains a rich source of 
potential drug targets within orphan receptors (oGPCRs) i.e. receptors whose 
ligands are unknown and whose physiological relevance remains 
undetermined [3, 4],
1.1.1 GPCR Classification
GPCRs can be categorised in reference to the type of stimulus that 
activates them: those that are activated in response to exogenous stimuli 
such as pheromones, tastes and odours (csGPCRs) or those that respond to 
endogenous molecules (endoGPCRs) [4]. GPCRs have been grouped in 
various ways over the years. Recent phylogenetic analyses divide the GPCR 
superfamily into 5 groups (the GRAFS classification) which only include 
receptors from the human genome [1]:
• Family G for glutamate-like receptors with 15 members
• Family R for rhodopsin-like receptors with 701 members (241 of which 
are non-olfactory)
• Family A for adhesion with 24 members
• Family F for frizzled/taste2 consisting of 10 frizzled receptors and 13 
group-2 taste receptors
• Family 8 for secretin with 15 members [5].
The rhodopsin-like family (family R) are the best characterised receptors both 
structurally and functionally and in relevance to this thesis, are the family to 
which the sphingosine-1-phosphate (SIP) receptors belong (Figure 1.1).
1.1.2 Structural Features of GPCRs
The prerequisites for classification as a GPCR are seven hydrophobic 
sequence stretches (25-35 amino acids in length) and the ability to associate 
with a G protein [3]. Typically, each GPCR consists of a single polypeptide 
chain variable in length with seven hydrophobic regions spanning the plasma 
membrane, with an extracellular N-terminal domain and an intracellular C- 
terminal domain. These transmembrane (TM) domains are believed to form 
a barrel shape in the membrane with three extracellular and three 
intracellular connecting loops. This barrel-shaped receptor is orientated in 
the membrane to provide a pocket in which small ligands can bind [6, 7].
In the majority of receptors belonging to the rhodopsin-like family there 
are a number of conserved structural features. For example, the Asp residue 
in TM-II and Asn in TMs-l and VII are highly conserved [8-10]. These 
residues function to keep the TM-II and -VII regions in close proximity to 
allow receptor activation [6]. Another conserved structural feature is the 
presence of a disulphide bond linking TM-III to the second extracellular loop 
[5] (Figure 1.2).
The C-terminal domains of GPCRs vary in length and typically contain 
amino acid residues that can be covalently modified by phosphorylation like 
serine and threonine. There are also cysteine residues within the C-terminal 
domain that can be modified by the addition of palmitic acid which can insert 
into the membrane forming a fourth intracellular loop, also known as 'helix 8’ 
[11, 12]. The N-terminal domains also vary in length and most contain an N- 
linked glycosylation motif (N-X-T/X).
The ligand binding site of these GPCRs depends on the structure of 
the ligand which varies greatly for the rhodopsin-like family of receptors. If 
the agonist is small like an amine or lipid then the binding site is believed to 
be within the TM pocket, whereas larger activators tend to interact with 
residues in the extracellular loop and N-terminal domain [6]. For example, 
the S1Pi receptor contains two Arg residues at positions 120 and 292 
respectively which form ion pairs with the phosphate group on S IP  and a Glu 
residue at position 121 which interacts with the quaternary amine group of 
S IP. In fact, a corresponding Glu residue has been identified in the other 
S IP  receptors [13].
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1.1.3 Receptor Activation
Although related, ligand binding and the subsequent signal 
transduction are distinguishable events. The consequences of ligand binding 
depend on the specific regions of the receptor bound, the type of receptor, 
and the structure and size of the ligand [6]. Tradition has placed receptors in 
either an inactive (quiescent) state or active (functional) state [14]. It is now 
widely accepted that there are varying degrees of receptor activation. 
GPCRs exist in an equilibrium between two states of inactive (R) and active 
(R*) [6] (Figure 1.3).
Efficacy is a term used to describe the level of change that occurs 
upon agonist binding to the receptor. Affinity describes the ligand's capacity 
for binding the receptor, which is expressed as its dissociation constant (Kd). 
An agonist displays positive efficacy as it evokes a functional response after 
receptor binding and a partial agonist displays relative efficacy which is 
expressed as a percentage of the effect accomplished by a full agonist (i.e. 
100%) [15]. Whereas an antagonist exhibits zero efficacy as it produces no 
activity when bound to the receptor, it also prevents the binding of agonists 
[16]. Recent evidence suggests that GPCRs have the ability exist in an 
active conformation without being ligand occupied. Ligands that bind and 
block this constitutive activity were previously described as antagonists but 
are now termed inverse agonists [17].
1.1.4 Heterotrimeric G proteins
In contrast to variety of ligands a GPCR can bind, there is a limited 
number of heterotrimeric G proteins (consisting of a, p and y subunits) with 
which they can associate. G proteins act as mediators of receptor activated 
signal transduction pathways. The pathways stimulated are determined by 
the type of G protein coupled to each receptor, which can associate with one 
or more type(s) of G protein [18]. There are 16 G« subunits that have been 
grouped into 4 families; G^s, G«i, G«q and Gai2/i3 . 5 Gp and 12 Gy subunits 
[19] (Table 1.1).
1.1.5 Heterotrimeric G protein Activation and Regulation
The association between GPCR and G protein is usually via second or 
third intracellular loop of the receptor [20, 21]. G proteins are activated by 
the binding of an agonist to its receptor which causes a conformational 
change that promotes the exchange of GDP for GTP in the guanine 
nucleotide binding site of the G« subunit [18, 22]. This interaction induces 
the dissociation of G„ from the Gpy subunits which remain bound to one 
another. The active (GTP-bound) G« subunit and the liberated py subunits 
then act as mediators of receptor-stimulated effector activation [18].
Ga subunits contain two domains: a GTP binding domain that exhibits 
GTPase activity and a unique helical domain concealed within the interior of 
the protein. G proteins are classified according to the organisation and 
properties of their a subunit. G^i and Gs differentially regulate adenylyl 
cyclase (AG). G«i inhibits AC activity whereas G«s stimulates it. Gaq 
activates phospholipase C (PLC) mediating calcium mobilisation and Gai2/is 
which are implicated in small G protein activation and cytoskeletal 
remodelling [6].
The Gp subunit contains seven so-called WD40 repeats within what is 
described as a 7-blade propeller structure. This is comprised of seven p- 
sheets containing four anti-parallel p-strands that form the “blades”. The N- 
terminal helix of the Gy subunit forms a coiled coil with the N-terminal helix of 
the Gp subunit. The structure of the Gpy complex remains the same 
regardless of interaction with the a subunit and is thereby regarded as a 
negative regulator of Ga activity [11, 18]. The Gpy itself subunit activates a 
vast array of proteins including PLCp, AC, PI 3-kinase and G protein-coupled 
receptor kinases (GRKs) [23] (Table 1.2).
G protein signalling is also subject to regulation by a family of proteins 
call regulators of G-protein signalling (RGS) that are characterised by a 130 
residue homologous region that binds preferentially to active G« subunits 
[24]. They function to attenuate GPCR signalling by inactivation of G 
proteins by acting as GTPase-activating proteins (GAPs) i.e. they accelerate 
GTP hydrolysis, so G« returns to its inactive GDP-bound state which is 
followed by the re-association of the heterotrimer. RGS proteins also exert
5
an antagonistic effect by physically preventing G proteins from activating their 
target. In addition to this, RGS proteins possess the ability to alter the 
number of free py subunits available to downstream effectors by increasing 
the affinity between G«and Gpy [16].
Ga proteins are also regulated by covalent modifications such as N- 
myristoylation and palmitoylation while Gy subunits are subject to prénylation. 
These alterations serve to target the subunits to the membrane but are also 
relevant in the interaction between subunits and with other proteins. 
Regulation of G« and Gy subunits by phosphorylation also occurs and this 
has implications for signal amplification [25]. The addition of ADP-ribose on 
a cysteine residue within the C-terminal domain of Gai proteins which causes 
the inhibition of G« activity by pertussis toxin is a useful tool for studying 
receptors coupled to this class of G« proteins [19, 26].
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Figure 1.1 Crystal Structure of Bovine Rhodopsin
Comparison of the predicted structure for bovine rhodopsin (green) 
and the x-ray crystal structure (blue) (taken from Vaidehi et af) [27].

Figure 1.2 Illustration of the Seven Transmembrane Domains Typical 
of GPCRs
Counter clockwise orientation of the seven transmembrane (TMI-VII) 
domains typical of GPCRs. In this arrangement the core is composed of 
TMII, III, V and VI with TMI and VII in the periphery [6].
9
&oo cnQ.oo
Gi
C0
3>»(/)1O) <DIJOE
0 )E
(0E(/)
CL
Figure 1.3 GPCRs Exist in Equilibrium between Inactive and Active 
States
GPCRs can adopt various conformations in equilibrium. The active 
state (R*) receptor can associate with G proteins whereas the inactive state 
(R) receptor cannot and an active conformation that forms spontaneously or 
through ligand binding (LR*). The relationship between LR* and R* for G 
protein results in receptor agonism, antagonism or inverse agonism (taken 
from Gbahou eta l) [28].
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Table 1.2 Gpy Effector Targets
Effector _____________ Ggy Ga
Io n  C h a n n e ls  +
1kg +G I R K 1 . 2 & 4  +
P h o s p h o lip a s e  +
P L G  p 1 -3  +  +
A d e n y ly l c y c la s e  T y p e  II &  IV  +
G R K s  +
P I 3  k in a s e  +
S h e  p h o s p h o ry la tio n  +
R a f-1  +
R a s -G E F  C D C 2 5  +
P la s m a  m e m b ra n e  +
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1.2 Regulation of GPCRs
The continued stimulation of a receptor results in a rapid decrease of 
responsiveness of the receptor to the same agonist. This is described as 
desensitisation and its purpose is to protect the cell from over-stimulation. 
Early desensitisation occurs seconds after receptor exposure to agonist and 
involves the covalent modification of the intracellular loops and/or C-terminal 
tail by phosphorylation [6 , 12]. Long term desensitisation entails receptor 
sequestration from the cell surface (internalisation) followed by eventual 
down-regulation (a reduction of total receptors in the cell) [29]. This is also 
associated with reduced mRNA and protein synthesis in addition to 
lysosomal and proteosomal targeted degradation of pre-existing receptors 
[30, 31].
1.2.1 Regulation of GPCRs by Phosphorylation
Covalent modification of the receptors by phosphorylation by 
intracellular kinases causes a rapid dissociation of the heterotrimeric G- 
p rote in from the GPCR. Agonist occupation of the receptor produces a 
conformational change that facilitates its phosphorylation by a family of 
proteins called G protein-coupled receptor kinases (GRKs). This results in 
the attenuation of GPCR signalling which described as homologous 
desensitisation. The targets for phosphorylation by these kinases are 
clusters of serine and threonine residues localised within either the C 
terminal tail or the third intracellular loop [32, 33].
The GRK family of kinases has seven members that share significant 
sequence homology. GRK1 (rhodopsin kinase) and GRK7 (cone opsin 
kinase) expression is limited to retinal cells and these are described as the 
visual GRKs [34]. The non-visual GRKs 2, 3, 4, 5 and 6  are expressed in 
many cell types [35]. Each GRK has a similar structural organisation: a core 
catalytic domain, and N-terminal containing an RGS-like domain thought 
important in substrate recognition, a catalytic domain and a C-terminal 
domain of variable length involved in plasma membrane targeting (in the 
case of GRK2, 3 and 5) [35]. GRK2 is known to phosphorylate many GPCRs 
and also contains a clathrin-binding domain within its C-terminus. The 
available evidence suggests that specific sites of phosphorylation have
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functional consequences for the regulation of a GPCR by different GRKs 
[36].
GRKs phosphorylate target GPCRs in an agonist-dependent manner 
which promotes the binding of cytoplasmic adaptor proteins called (3- 
arrestins. Binding of p-arrestin sterically blocks receptor association with the
heterotrimeric G protein complex allowing p-arrestin-mediated association 
with clathrin [37] thereby attenuating the signal to effector proteins and 
targeting the receptor for internalisation (which is to be addressed in the next 
section), p-arrestins are also emerging as scaffolding proteins [38] that 
facilitate the transactivation of activation of mitogen-activated protein kinases 
(MARK) such as the extracellular signal-related kinases (ERK1 and ERK2) 
[39].
Other MAPK pathways identified are p38 protein kinases (a, p, y and 
Ô) and c-Jun N-terminal kinases (JNKs) of which there are three encoded by 
separate genes JNK1, 2 and 3. Activation of JNK occurs when threonine and 
tyrosine residues are phosphorylated by MAPK kinases like MKK4 and MKK7 
which in turn are phosphorylated by MAPKK kinases like MEKK1 and ASK1 
[40, 41]. p-arrestin 2 acts as a scaffolding protein and has been shown to 
interact with JNK3, thereby bringing the MAPKs under the control of GPCRs 
[42].
Stimulation of GPCRs leads to an increase in intracellular second 
messengers such as cAMP and Ca^^, and hence the activation of second 
messenger-dependent kinases such as cAMP-dependent protein kinase 
(PKA) and protein kinase C (PKC), which respond by phosphorylating 
GPCRs thereby functioning as a feedback mechanism [12]. These kinases 
phosphorylate GPCRs on a serine or threonine present within the 
intracellular loops and C-terminal tail of GPCRs [32] in an agonist- 
independent manner, this is termed heterologous desensitisation. PKC and 
PKA have also been shown to modulate the activity of GRKs [43]. PKC- 
induced phosphorylation of GRK2 results in increased phosphorylation of 
receptor but not soluble proteins, indicating that PKC-mediated 
phosphorylation of GRK2 induces its translocation to the plasma membrane 
[44, 45]. Conversely, GRK5 activity toward receptors and cytosolic
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substrates is inhibited upon PKC phosphorylation [46]. PKA activity which is 
induced by Gs-coupled receptors also leads to a direct phosphorylation of 
GRK2 which also enhances its activity [47].
1.2.2 Regulation of GPCRs by Internalisation
GPCR signalling is attenuated by receptor phosphorylation, which is 
sufficient to interfere with the coupling of the heterotrimeric G-protein to the 
receptor. It is a rapid process occurring in the order of seconds, allowing 
interaction with the arrestins, permitting sequestration of the receptor from 
the cell surface to intracellular vesicles. Resensitisation eventually occurs 
due to the subsequent recycling of the receptor back to the plasma 
membrane following agonist removal [48, 49]
The arrestin family is well conserved in eukaryotes and consists of at 
least four members two visual arrestins (rod and cone) expression of which is 
mainly restricted to the retina and p-arrestins1 and 2  that are expressed 
ubiquitously [37]. GPCRs are able to bind different arrestin isoforms with 
different affinities, thus it may be the presence of various p-arrestin isoforms 
expressed in the cell that controls the capacity of a specific GPCR to 
internalise [50].
p-arrestins act as adaptor molecules that facilitate the clathrin- 
mediated endocytosis of GPCRs. p-arrestin 1 has been shown to interact 
with the tyrosine kinase c-Src via its Src homology domain (SH1) and using a 
kinase dead mutant, blocked receptor internalisation and Src-mediated 
phosphorylation of dynamin. Src activity on other substrates was unaffected, 
thus implicating p-arrestin in receptor internalisation [51]. It was experiments 
involving the p2-adrenergic receptor (P2AR) interaction with p-arrestin and 
dynamin I mutants which blocked endocytosis, that first indicated their 
involvement in the targeting of GPCRs to clathrin-coated pits [52]. Dynamin I 
is a large GTPase distributed in the surface of a newly formed clathrin-coated 
pits and is involved in vesicle closure, p-arrestin binds to clathrin with a high 
affinity but also binds adaptor proteins that mediate vesicle recruitment, 
particularly the p2-subunit of the heterotetromeric AP2 adaptor complex [53]. 
Resensitisation occurs in the presence of a GPCR-specific phosphatase
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within the endocytic compartment which causes the dephosphorylation of the 
receptor and subsequent recycling back to the cell surface or degradation 
[39] (Figure 1.4).
Repeated or prolonged agonist exposure results in down-regulation 
which is induced after a period of hours to days [54]. This negatively 
regulates GPCR signalling by lowering the number of receptors present in 
the cell either by lysosomal or proteosomal-mediated proteolysis [29, 55]. 
P2AR has been studied extensively and these studies indicate that ligand- 
induced activation can alter receptor transcription [56] and RNA stability [57].
The mechanism for endocytosis is receptor- and cell type-specific but 
many GPCRs undergo internalisation via clathrin-coated pits. For example, 
the P2AR will internalise via the clathrin-coated vesicle route but will also 
endocytose into distinct membrane domains called caveolae depending on 
the cell type in which it is expressed [58, 59]. Caveolae are omega-shaped, 
specialised domains of the plasma membrane containing a protein called 
caveolin. These domains are Triton X-100 insoluble due to a high 
concentration of cholesterol, sphingomyelin and glycosphingolipids. 
Caveolae are extremely common in certain cell types such as endothelial and 
smooth muscle cells [60]. These specialised membrane domains have been 
implicated in signal transduction as well as endocytosis. A number of 
signalling molecules have been shown to aggregate there including G 
proteins [61], AC [59], eNOS [62], PKC [63], GRK2 and 3 [61].
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Figure 1.4 Model for GPCR Internalisation via Clathrin-coated pits
Agonist (Ag) binding causes a conformational change which allows the 
dissociation of the heterotrimeric G protein. The agonist occupied receptor is 
then a substrate for intracellular kinases to phosphorylate the C- terminus. 
Phosphorylation promotes the binding of adaptor molecules such as arrestins 
and AP-2, preventing receptor association with G proteins and targeting the 
receptor to clathrin-coated pits for internalisation into an endocytic vesicle 
where the receptor is de-phosphorylated.
The receptor can be recycled to cell surface or if agonist exposure 
continues targeted to the lysosome for degradation. If agonist exposure is 
prolonged, this results in down-regulation, which is a decrease in the total 
number of receptors present in the cell.
GRK= G protein coupled receptor kinase 
D= Dynamin I
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1.3 Lysophospholipîds
Lysophospholipids are not only metabolites of phospholipid synthesis 
but are potent activators of widely expressed GPCRs. The best 
characterised are lysophosphatidic acid (LPA) and sphingosine-1 -phosphate 
(S1P) (Figure 1.5). LPA is a lipid with a glycerol backbone and a long 
saturated or unsaturated fatty acid chain. LPA can be generated either 
intraceilularly or extracellularly and this is mediated by various enzymes 
including phospholipases. S IP  is composed of a sphingoid backbone and a 
phosphate group. Both S IP  and LPA function as autocrine and paracrine 
mediators of cell function and are capable of binding to multiple receptors 
eliciting among predominantly growth-related responses. However, the focus 
of this thesis will be on the actions of SI P [64, 65].
1.3.1 Sphingosine-1-Phosphate (SIP)
Sphingosine was named by its discoverer J.L.W. Thudichum in 1884 
after the Greek mythological creature the Sphinx due to it mysterious 
qualities [6 6 ]. High levels of sphingosine are toxic to cells and so low levels 
are maintained by specific enzymes that metabolise sphingosine into non­
toxic derivatives. One such derivative, D-ef/7/yo-sphingosine-1 -phosphate 
(S IP) is produced by the phosphorylation of sphingosine which is then 
subsequently degraded and recycled. It was first thought that S IP  was only 
an intermediate in the detoxification of sphingosine but over the past few 
decades S IP  has emerged as a crucial modulator of lipid signalling [67, 6 8 ].
In addition to mammals, S1P and related sphingoid lipids have been 
detected in plants [69, 70], worms, flies, slime moulds and yeast [71]. The 
discovery that S IP  regulates proliferation [72], suppresses programmed cell 
death [73] and the subsequent cloning and identification of cell surface 
receptors to which S IP  binds [74-76] has lead to numerous studies linking 
S IP  to physiological and pathophysiological processes such as cancer, 
angiogenesis, vascular permeability and transplant rejection. The ubiquity of 
S IP  and its receptors and the evolutionary conservation of S IP  metabolism 
demonstrates its importance as a signalling molecule [67].
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1.3.2 S IP  Metabolism and Secretion
Sphingolipids are ubiquitous constituents of eukaryotic membranes. 
Sphingomyelin (SM) is metabolised by sphingomyelinases to produce an 
acylated sphingoid base called ceramide. Déacylation of ceramide forms 
sphingosine which can be phosphorylated by sphingosine kinases (SphKs) to 
yield S1P [6 8 , 77]. S1P is irreversibly degraded in the endoplasmic reticulum 
by 81P lyase to ethanolamine and hexadecenal [78]. Alternatively, S IP  can 
be converted back to sphingosine by specific phosphatases (Figure 1.6) [79, 
80].
All the enzymes involved in S IP  metabolism are conserved from yeast 
to man [6 8 ]. The evidence to date suggests that S IP  levels are 
predominantly regulated by its synthesis from sphingosine by SphKs rather 
than its degradation by S1P lyase [81] and S IP  phosphatase [82]. The basal 
level of S IP  in cells is usually low and an increase in S IP  levels consistently 
corresponds with an increase in SphK activity [83].
1.3.3 SphK Regulation
The first sphingosine kinases discovered were cloned from 
S.cerevisiae. The genes Lcb4 and Lcb5 encode a sphingolipid long chain 
base (LCB) kinases, which were found to be unrelated to any known protein 
thus revealing a new class of lipid kinase [84]. This lead to the search for 
mammalian homologues, of which the murine was the first isolated. 
Subsequently the human homologue SphKI (hSphKI) was cloned [83]. Both 
have similar tissue distributions and are highly expressed in the lung and 
spleen. SphKI contains no transmembrane domains or signal sequence and 
is found primarily in the cytosol [85].
Based on sequence homology to SphKI another isoform termed 
SphK2 was cloned from both humans and mice. SphK2 expression is 
detected in most adult tissues with the heart, kidney and testis showing the 
highest levels of expression. Both isoforms have five evolutionary conserved 
domains (named C1-C5); regions C1-C3 are a unique catalytic domain with a 
ATP binding site within C2 (Figure 1.7). In addition, the 2 isoforms of SphK 
differ in developmental and tissue expression which implies they may have 
distinct functions [8 6 ].
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SphK is activated by a number of agonists including epidermal growth 
factor (EGF) [87] platelet-derived growth factor (PDGF) [8 8 ], nerve growth 
factor (NGF) [89-91], tumour necrosis factor a (TNFa) [92], basic fibroblast 
growth factor (bFGF) [90], serum [8 8 ], phorbol 12-myristate 13-acetate 
(PMA), S IP  itself [93] and other activators such as protein B cell lymphoma 
gene-2 (Bcl-2) [94]. SphK2 contains four transmembrane domains as 
predicted by hydropathy studies, though like SphKI most of its activity is 
detected in the cytosol despite the fact their substrate is membrane-localised 
[8 6 ]. However, a more recent study reveals that SphK2 has a functional 
nuclear localisation signal (NLS) and its activity is predominantly localised in 
the nucleus [95]. However, these differences in SphK2 localisation were 
observed in different cell types where the NLS-mediated translocation of 
SphK may be prevented by interaction with another protein.
It has been shown that PDGF causes the translocation of SphKI to 
the leading edge of the lamellipodia in murine embryonic fibroblasts (MEFs) 
[96]. It has also been demonstrated in human embryonic kidney cells (HEKs) 
that treatment with PMA triggers the translocation of SphKI to the cell 
membrane which corresponds with an accumulation of extracellular SIP. 
This indicates that SphKI action on membrane-localised sphingosine allows 
the crossing of S IP  through the membrane, despite the polar nature of its 
head group [93].
Studies using S.cerevisiae identified an ATP-binding cassette protein 
called yeast oligomycin resistance gene (YOR1) that rendered the cells 
resistant to the apoptotic effect of sphingosine. The accumulation of 
sphingosine is prevented by pumping S IP  out of cells [97]. In mammals, 
haematopoietic cells such as activated platelets, monocytic and mast cells 
are known to actively secrete S IP  [98]. Interestingly, platelets are the only 
mammalian cells that lack S IP  lyase activity [99].
It has been shown recently that permeabilised platelets activated by 
thrombin release SIP. This requires the presence of bovine serum albumin 
(BSA) and indicates that S1P release may be a carrier-mediated process 
[100]. Circulating S IP  is primarily bound to high and low density lipoproteins 
though it can also bind albumin [101, 102]. The concentration of S IP  in 
plasma ranges between 0.2-0.5jiM. However the concentration in serum is
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much higher (1-5pM) and has been attributed to its secretion from activated 
platelets [103, 104]. This is much higher than the Kd for binding of S1P to the 
extracellular surface receptors identified for this ligand which is in the order of 
8-25nM [105, 106]. Specific lipoproteins are associated with cardiovascular 
diseases such as atherosclerosis, so measurement of S IP  content in 
lipoproteins in additon to the total plasma and serum content is important in 
characterisation of these diseases [107].
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Figure 1.5 The Chemical Structures of Sphingosine-1-phosphate 
(S1P) and Lysophosphatidic Acid (LPA)
Both 81P and LPA are synthesised by cells de novo or through 
intermediate metabolism.
25
SIPLPA OH
;c=o
o
26
Figure 1.6 The Metabolism of Sphingosine-1-phosphate (SIP)
Pathways of S IP  metabolism. The de novo synthesis of S IP  is 
initiated by the condensation of serine and palmitate to 3-ketosphinganine 
which is rapidly reduced to dihydrosphingosine (DHS). The enzyme 
ceramidase catalyses the N-acylation of DHS to dihydroceramide. Ceramide 
is generated by the introduction of a 4-5 trans double bond. Sphingosine is 
formed by the déacylation of ceramide or by the liberation from 
sphingomyelin. Ceramide can be converted into sphingosine by the addition 
of phosphocholine. S1P is produced by the phosphorylation of sphingosine 
by SphKs. S1P can be converted back to sphingosine by S IP  phosphatase. 
Conversely, S1P can irreversibly degraded by S IP  lyase [99].
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Figure 1.7 The Structural Composition of Sphingosine kinases 1 and 
2
SphKI and 2 have five conserved domains (01-05) with the unique 
catalytic domain contained with 01-03. The ATP binding site (SGDXK 17-21 
(R)) is present within 02. Unlike SphKI, SphK2 contains four 
transmembrane domains, a nuclear localisation sequence (NLS) and a Bcl-2 
homloogy domain (BH3) [6 8 ].
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1.4 Identification of S1P Receptors
S1P receptors are involved in diverse cell signalling pathways 
controlling many growth-related or cytoskeletal cell processes such as 
apoptosis [78], angiogenesis [67], inflammation [108], proliferation [109] and 
migration [110, 111]. S IP  receptors belong to a family termed the 
Endothelial Differentiation Gene (EDG) family. The first EDG receptor was 
identified in 1996 during a search for genes expressed predominantly in the 
ventricular zone (VZ) of cerebral cortex and was called ventricular zone gene 
1 (VZG-1) [112], This was shown to be a GPCR with high affinity to LPA 
[113]. The search for homologues ensued and it was realised that EDG-1 
and VZG-1 (EDG-2) were related [114], EDG-1 was discovered as an 
abundant protein expressed on endothelial cells, which was believed to have 
a potential role in endothelial differentiation. It was cloned as an immediate 
early gene termed edg-1  (endothelial differentiation gene-1 ) and the resulting 
polypeptide contained seven transmembrane stretches indicating that it was 
a GPCR [115].
The exogenous agonist for the EDG-1 receptor remained a mystery 
until 1998, when two groups identified the lipid S1P as a high affinity ligand. 
HEKs over-expressing EDG-1 were observed to have similar morphology to 
endothelial cells, increased expression of cadherins and extensive adherens 
junctions. S IP  promotes the formation of capillary-like networks in 
endothelial cell cultures. These responses were dependent on S IP  and the 
small GTP binding protein Rho [76, 116].
The other receptors were subsequently cloned using degenerate PCR 
strategies and cDNA libraries [117, 118], and to date, there are eight EDG 
receptors identified that have been re-named according to their ligand 
specificity. There are five EDG receptors that bind S IP  with high affinity; 
81 Pi (EDG-1), S IP 2 (EDG-5), S IP 3 (EDG-3), S IP 4 (EDG-6 ) and S IP 5 
(EDG-8 ). The other three EDG receptors are high affinity receptors for LPA 
called LPAi (EDG-2), LPAg (EDG-4) and LPA3 (EDG-7) [119] (Figure 1.8).
The EDG family can be categorised into three groups according to 
their amino acid sequence similarity:
1. S IP 1, S IP 2 , S IP 3 and S IP 5 which are approximately 50% identical,
2. L P A i ,  L P A 2 ,  and L P A 3  which are approximately 55% identical,
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3. S I P 4  which is 35-42% identical to the other EDG receptors [120]
(Figure 1.9).
1.4.1 S I P Receptor Signalling
S IP  receptors are integral membrane proteins with seven 
transmembrane domains typical of GPCRs with an extracellular N-terminus 
and an intracellular C terminus. They share approximately 50% homology to 
each other. Each receptor couples to one or more signal transduction 
pathways via heterotrimeric G-proteins [119, 121].
81 Pi is expressed in most mammalian tissues but is highly expressed 
in endothelial cells the heart, lungs and the brain. 81 Pi signalling is 
associated with the inhibition of AC, the mobilisation of calcium through PLC 
activation [122], the activation of Ras and the activation of PI 3 kinase [123, 
124]. These effects are all mediated by the actions of the py subunit of G, 
except the inhibition of AC which is regulated by G« [125] and are pertussis 
toxin sensitive. S IP 1 also exerts control of the small GTPase Rac [124, 126]. 
S IP 2 and 8 IP 3 couple to G|, G12/13 and Gq [127]. 8 IP 3 is expressed in many 
tissues especially heart, lung, kidney and spleen [64]. 8 IP 3 activation results 
in Ras and Rac activation through Gq and its activity can be partially blocked 
by pertussis toxin suggesting an a Gj component [128]. Like 8 IP 3, 8 IP 2 is 
ubiquitously expressed showing higher expression levels in heart and lung 
tissues [64]. 8 IP 2 activates ERK and PLC via Gj but also activates AC [129]. 
8 IP 2 also stimulates c-Jun amino terminal kinase (JNK) and p38 activity in a 
pertussis toxin insensitive manner [130].
8 IP 4 and 8 IP 5 signalling pathways have not been extensively 
characterised. Both 8 IP 4 and 8 IP 5 are believed to couple to Gj and G12 
[131-133]. 8 IP 4 expression is mostly confined to lymphoid tissues and 
platelets [134] and 8 IP 4 has been shown to stimulate Cdc42, PLC and ERK 
in a pertussis toxin sensitive manner. 8 IP 4 also activates Rho via G 1 2 /1 3  
[131, 135, 136]. S IP 5 expression is confined to the central nervous system 
and the skin [132] and is associated with AC inhibition and unusually, the 
inhibition of ERK. 8 IP 5 also promotes JNK activity through its interaction 
with G12 [132, 133] (Figure 1.10).
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Distinct receptor expression patterns and their ability to couple to 
multiple G proteins that signal to a range of effector proteins allows S1P 
receptors to regulate many cellular processes in a specific manner to give a 
co-ordinated cellular response to S1P [6 8 ]. S1Pi receptor signalling has a 
particularly important role in development, angiogenesis and migration and 
these aspects of S1Pi signal transduction will be addressed later.
1.4.2 Orphan GPCRs (oGPCRs) with homology to S IP  and LPA 
Receptors
In addition to the more conventional members of the EDG family there 
are a number of receptors identified which are closely related. These include 
GPR3, GPR6 , GPR12, GPR23 and GPR63. They share 57-61% sequence 
identity. The receptors GPR3, 6 , 12 and 63 have been identified as S1P 
receptors [137, 138].
The oGPCR GPR45 is a mammalian homologue of a LPA receptor 
identified in X. laevis [139]. Also, PSP24 (cloned from Xenopus) has been 
identified as a LPA receptor but is not functional in mammals [140]. GPR6 8  
which was cloned from an ovarian cancer cell line has been identified as a 
sphingosylphosphocholine (SPC) receptor [141]. The availability of 
information on the human genome has accelerated the identification of 
receptors. Pairing receptor with ligand and discovering the signalling 
pathways which regulate will aid the search for therapeutic targets [142].
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Figure 1.8 The EDG Receptor Family and Related Receptors
Phylogenetic tree representing receptors with high and low affinities 
for the ligands: SIP, LPA and sphingosylphosphocholine (SPC). It also 
shows related receptors for which the agonist is undetermined (Taken from 
Kostensis) [143].
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Figure 1.9 The EDG Family Amino Acid Alignment
The amino acid sequence of human EDG receptors 1-7. EDG-1,-3, - 
5, - 6  and - 8  are high affinity for S1P. EDG-2,-4 and -7 are high affinity for 
LPA. The black shading highlights the identical residues and the grey 
shading represents similar residues.(take from Pyne and Pyne, 2000) [77].
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Figure 1.10 S1P Receptor Signalling
1. SI Pi couples exclusively to G j, it regulates Rac via PKB,
2. SI p 3 couples to G|, Gq and G13, it activates Rac,
3. S IP 2 couples to Gi, Gqand G13 but unlike S IP 3 it inhibits Rac,
4. S IP 4 couples to Gi and G13 , and activates adenylyl cyclase via an 
unknown mechanism,
5. S IP 5 couples to Gi and G12, it inhibits ERK activation and promotes 
JNK activity, (adapted from Taha eta!) [123].
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1.5 The Small G protein Superfamily
Small GTP-binding proteins are monomeric G proteins with molecular 
masses in the order of 20-40kDa. The Ras proteins were first identified as 
viral oncogenes (v-Ha-Ras and v-KI-Ras) [144, 145]. Their counterparts in 
humans were identified in carcinomas and were shown to stimulate 
transformation and proliferation [146-149]. To date there are more than a 
hundred identified small G proteins in eukaryotes from yeast to human [150]. 
The members of this superfamily are categorised into five families:
• Ras Family are involved in gene expression,
• Rho Family (Rho/Rac/Cdc42) regulate cytoskeletal reorganisation,
• Rab and Sarl/Atf Family regulate vesicular trafficking,
• Ran Family regulate nucleoplasmic transport and microtubule
dynamics during cell cycle processes [150].
1.5.1 Small G protein Regulation
Small G proteins share similar structural organisation with other G 
proteins: a consensus amino acid sequence responsible for interaction with 
GDP and GTP and intrinsic GTPase activity. The Ras, Rab and Rho family 
have C-terminal tails that undergo post-translational modifications with 
isoprenoid and palmitate lipid groups [151].
By cycling between GDP- and GTP-bound states, small G proteins 
function as molecular switches. The exchange of GDP for GTP causes a 
conformational change that allows their interaction with downstream 
effectors. The rate limiting step in GDP/GTP exchange is the dissociation of 
GDP which is enhanced by guanine nucleotide exchange factors (GEFs). 
GEFs vary in substrate specificity, such as son of sevenless (Sos) which 
activates Ras and Rac. The GEFs Dbl and Vavl show wider substrate 
activity by acting on Rho, Rac and Cdc42 [152]. GAPs, (GTPase-activating 
proteins) function to stimulate the small G protein's intrinsic GTPase activity 
thereby favouring the inactive state. The Rho GTPases in particular are 
subject to further regulation by GDP dissociation inhibitors (GDIs) which 
sequester the GDP-bound form so the G protein remains soluble despite any 
lipid modification [153] (Figure 1.11). The activation of this family of proteins 
is thereby tightly regulated by both positive and negative mechanisms.
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1.5.2 The Rho GTPases
The mammalian Rho GTPase family consists of at least 20 members 
(Figure 1.12) and their activation stimulates signalling pathways leading to 
regulation of the cytoskeleton, cell cycle, gene transcription, cell polarity and 
vesicle transport. The role of Rho GTPases in regulation of the cytoskeleton 
was elucidated using C3 toxin which ADP-ribosylates an Asn residue within 
the effector region of RhoA [154] which lead to rapid changes in the 
morphology of the cell caused by re-organisation of the actin microfilaments. 
Rho proteins were subsequently identified as regulators of cytoskeletal 
operations [155, 156] such as stress fibre formation, focal adhesion dynamics 
and muscle contraction [157, 158], whereas Rac and Cdc42 were discovered 
to be involved in the regulation of other cytoskeletal processes such as the 
formation of lamellipodia and filopodia, respectively [159-161].
It has been estimated that there are as many as fifty GEFs, forty GAPs 
and forty effectors identified for Rho-like G proteins [162, 163]. The GEFs 
identified hitherto have a conserved motif called the Dbl-homology domain 
(DH) and a pleckstrin homology domain (PFI) which is involved in cellular 
localisation with PIP2 [152, 164]. In addition to activation of GTPases GEFs 
also participate in the selection of downstream targets by either binding with 
effectors or scaffold proteins that complex with components of the targeted 
pathway. For instance, the Rac GEF Tiam-1 (T-lymphoma invasion and 
metastasis) stimulated the accumulation of IB2  which is a scaffold protein for 
the p38 mitogen-activated protein kinase cascade but also enhances ERK 
signalling [165].
1.5.3 Rho, Rac, Cdc42 and Migration
The role of the small G proteins Rac, Rho and Cdc42 in migration is 
perhaps the best characterised of their functions. Rac activity is localised at 
the front of the cell (leading edge) to regulate localised actin polymerisation 
required for membrane extension. Rho is required to generate contractile 
force which results in the rounding of the cell body and microtubule 
polymerisation at the rear of the cell. Cdc42 is necessary to establish polarity 
of the cell and filopodial protrusions [162, 166]. All these actions must be co­
ordinated spatially and temporally to produce a net forward movement of the
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migrating cell (Figure 1.13). In addition to this, all three GTPases induce the 
assembly of integrin-based matrix-adhesion complexes ([161].
PI 3-kinase and its product PIP3 are known to influence cell polarity 
and migration [167]. The production of PIP3 increases level of GTP-bound 
Rac in various cell types by interaction with the Rac GEFs Vav and Sos-1 
[168, 169]. Expression of constitutive Rac in fibroblasts results in extensive 
lamellipodia and membrane ruffling but not activation of other Rac-mediated 
signals like the JNK pathway [170]. Rac and PI 3-kinase interact with each 
other directly and GTP-bound Rac stimulates PI 3-kinase promoting PIP3 
production, thus implying the existence of a positive feedback loop [171]. 
Another Rac/Cdc42 GEF called PIX is also regulated by PIP3 . At the leading 
edge of the cell, PIX promotes actin polymerisation and interacts with the 
Rac effector p65PAK which is believed to control focal adhesion turnover 
[172]. p65PAK phosphorylates and actives LIM kinase (LIMK) which then 
phosphorylates and inactivates cofilln [173]. Cofilin functions to promote 
actin filament treadmilling at the leading edge of migrating cells. Like 
p65PAK, p160Rho kinase (ROCK) a Rho substrate, can phosphorylate and 
activate LIMK which leads to the phosphorylation and inactivation of cofilin, 
thereby facilitating the stabilisation actin filaments within actin-myosin 
filament bundles [174]. ROCK phosphorylates and inactivates myosin light 
chain kinase (MLCK) [175] which further promotes the cross-linking of actin- 
myosin bundles, thus generating contractile force and also encouraging 
detachment at the rear of the cell [176]. Another downstream target of Rho is 
mDia which is a scaffold protein that cooperates with ROCK in the assembly 
of actin-myosin filaments [177].
Both Rac and Cdc42 regulate the actions of WASp or WAVE proteins. 
WASp (Wiskott-Aldrich Syndrome protein) is a downstream target of Cdc42 
that interacts directly with the Arp2/3 complex, a ubiquitous activator of actin 
polymerisation in eukaryotic cells [178, 179]. Additionally, Rac interacts with 
WASP-like proteins WAVE (WASP family verpolin homology) indirectly and 
activates the Arp2/3 complex via interaction with an Nck-adaptor complex 
[180, 181] (Figure 1.14). It is at present unclear how Rac and Cd42- 
mediated activation of Arp2/3 results in morphologically different structures 
[166].
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Rho GTPases also regulate microtubule dynamics which are important 
in continual migration which requires established cell polarity [162]. A role for 
Rho GTPases in microtubule regulation was realised when it was discovered 
that the chemical nocodazole, which interrupts microtubules, caused the 
activation of Rho. Furthermore, the removal of nocodazole from cells 
resulted in the activation of Rac [182]. Rho is also implicated in the 
stabilisation of microtubules by capping [183] whereas Rac stimulates 
microtubule elongation via p65PAK-mediated phosphorylation and 
subsequent inactivation of stathmin (a microtubule destabilising protein) 
[184]. Although most of the evidence available points to a role for the Rho- 
like GTPases in determining cytoskeletal dynamics with respect to the 
regulation of migration, it is becoming clear that they function in many facets 
of cell morphology and maintenance.
1.5.4 Regulation of Endocytic Traffic by Rho-like GTPases
The small G protein families of Rab and Arf have crucial functions in 
vesicle trafficking and budding respectively [150]. There is also evidence of a 
role for Rho-like GTPases in various aspects of endocytosis. Internalisation, 
the budding off of the plasma membrane represents the initial step in 
endocytosis. Clathrin-mediated internalisation is the most studied form of 
endocytosis where receptors are clustered into clathrin-rich patches which 
are pinched off to form coated vesicles. This process does not seem to 
require the presence of Rho GTPases but they contribute to the organisation 
and efficiency of the process [185].
Rac stimulates the production of PIP2 through the activation of Pl-4,5 
kinase this mediates the dissociation of the capping protein from the barbed 
end of actin filaments [186]. Cdc42 is believed to bind directly with the 
coatomer binding domain, this interaction is important for golgi transport and 
the formation of vesicles, and if disrupted causes defective protein sorting 
and transport [187, 188].
Internalisation may also occur by mechanisms that are independent of 
clathrin. As stated in section 1.2.2, caveolae are associated with actin and 
many receptors and signalling molecules can localise there including 
activated forms of Rac and RhoA [189]. The most widely researched
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example of Rho-like GTPase-mediated internalisation is phagocytosis which 
is coordinated by Rac and Cdc42 [190, 191]. Receptor internalisation can 
also be mediated by glycosyl-phosphatidylinositol (GPI) which is dependent 
entirely on Cdc42 function [192].
1.5.5 Integrin Signalling
Another important aspect of Rho GTPase function is cell adherence. 
The proliferation of most normal cells requires in addition to growth factors, 
adherence to the substratum [193]. Integrins are heterodimeric 
transmembrane receptors that control the adhesion of cells to extracellular 
matrix (ECM) proteins such as laminin, collagen, fibronectin and vitronectin. 
The extracellular regions of the a and p subunits are non-covalently linked to 
form a globular head which interacts with ECM components in a specific 
manner determined by the make up of the heterodimer of a and p subunits of 
which there are over 20 combinations identified [194, 195]. integrin signalling 
mediates important cell fate decisions. The cell integrates information from 
both the ECM and growth factor receptors to regulate cell migration via 
signalling intermediates.
Fibroblastic, epithelial and endothelial cells have to be in contact with 
the appropriate ECM proteins to survive. Integrin receptors possess short 
cytoplasmic tails without enzymatic activity but are able to connect to 
signalling complexes via adaptor proteins and the cytoskeleton through 
structural proteins such as vinculin, talin and a-actinin which bind to F-actin 
[195, 196]. Integrin-mediated adhesion can influence calcium levels, activate 
Focal adhesion kinase (FAK), PKB, PKC, MAPK Kinase (MEK) and the Rho- 
like GTPases [193, 196-198].
Fibronectin mediates adhesion through asPi and avps integrin 
receptors [199] and adhesion of fibroblasts to fibronectin induces the 
activation of Rac and Cdc42 leading to downstream PAK activity which 
causes cell spreading [200, 201]. The Rac GEF Vavl has been implicated in 
integrin-mediated activation of Rac and Cdc42 in haematopoietic cells [202]. 
Sos can be recruited to adhesion complexes through FAKP130*^®® or She 
which also links integrin signalling to Rac activation [169]. Addition of S IP  to
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fibroblast cells was shown to increase fibronectin assembly and binding of 
the cell the the ECM and fibronectin assembly, suggesting a G i2/i3-coupled 
receptor is responsible for the observed effect, such as S I P 2  and S I P 3  [203].
Vitronectin mediates adhesion via the integrin receptors avPs, otvPi and 
avp5 [199]. The integrin dimer avP3 has been demonstrated to promote 
migration through the PI 3-kinase/PKB pathway when activated by vitronectin 
[204]. In addition to this cells adhering to fibronectin via avPi and to 
vitronectin through interaction with avP3 show increased levels of Bcl-2 
transcription which promotes survival [205].
1.5.6 S IP 1 and Rac Activation
The link between S IP 1 signalling and Rac activation has been 
reported widely but the mechanism remained unknown till Lee and 
colleagues proposed a PKB-dependent mechanism. PKB phosphorylates 
substrates that contain the consensus sequence RXRXXS/T [206] including 
eNOS [207], GSK-3p (glycogen synthase kinase) [208], Bad [209] and Rac 
[197]. The model proposed involves activation of the Gj pathway via S IP  
binding to 81 Pi which results in PI 3-kinase activation and subsequent 
translocation of PKB to the plasma membrane [210]. PKB is activated by 
phosphorylation at 8er473 and Thr308. PKB is then believed to 
phosphorylate 81 Pi at Thr236 which is located in the third intracellular loop. 
It is this covalent modification of 81 Pi which is implicated in Rac activation 
and subsequent actin assembly (Figure 1.15) [126]. Further evidence that 
the PKB signalling is essential in the ability of 81P to activate Rac is the 
finding that siRNA mediated reduction of endogenous R ad  expression 
significantly reduces 81P-mediated phosphorylation of PKB as well as 
downstream substrates eN 08 and G8K3p. Expression of the dominant 
negative from of the Rac GEF Tiam-1 significantly blocks SIP-mediated 
R ad  activation. This indicates that 81P-induced Rac activation is 
dependent on Tiam-1 activation and implicates a role for 81P-mediated 
activation of PI 3-kinase [124].
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1.5.7 The Role of S IP  in Migration
Migration is an essential process for all multicellular organisms not 
only in embryonic development and but also for the immune response, 
angiogenesis and wound healing. The Rho-like GTPase family have a 
crucial role in the signalling pathways that regulate cell migration [162]. S IP  
is a potent inducer of cell migration and can act alone or as a co-mitogen 
(e.g. with VEGF or bFGF). S IP  stimulates migration of endothelial cells 
derived from vasculature over a broad range of concentrations from 
nanomolar to micromolar [211] and more recently LPA has also been shown 
to stimulate transmigration of endothelial cells on gelatine and collagen- 
coated filters but not through fibronectin or vitronectin-coated filters. This 
reveals how interaction with ECM proteins may influence the cell's migratory 
abilities which suggests a role for LPA in angiogenesis [212].
81 Pi has been implicated in both endothelial and smooth muscle cell 
migration [211, 213]. Flowever, 81P receptor signalling differentially 
regulates the small GTPases Rac and Rho which results in dynamic cycles of 
MLCK activation and inactivation leading to the formation of stress fibres and 
membrane ruffles [214]. 81 Pi, 81 P 2  and 81 P 3  expression correlates with 
Rac activation status as shown in Chinese Flamster Ovary cells (CHOs). 
81 Pi and 81 P 3  activate Rac regulating the formation of lamellipodia thereby 
inducing cell migration. In addition to this, in vascular smooth muscle cells 
(V8 MC) over-expression of 81 Pi enhances 81P-induced migration and 
proliferation [213]. It has been suggested that 81 Pi and 81 P 3  -induced 
endothelial migration is mediated through Rho-dependent activation of avp3 
and Pi-containing integrins. Interestingly though, expression of both 
receptors is necessary for Rho activation, clustering of integrins and 
subsequent cell spreading and migration [215].
S IP 2 activity has a negative impact on cell migration, by inhibiting the 
activation of Rac and abolishing membrane ruffling [216]. This has also been 
demonstrated in V8 MCs where 81P2 is highly expressed. These cells 
proliferate in response to 81P but do not migrate [217, 218]. The 81P2 
receptor’s inhibitory effect on cell migration was also demonstrated in a 
glioblastoma cell line over-expressing 81P2 . S IP 2 mediates inhibition of 
migration in response to S IP  was found to occur in a ROCK-dependent
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manner but, in contrast to other studies, this was not accompanied by a 
concurrent inhibition of Rac activity [219].
S IP 2 also utilises the tumour suppressor phosphatase PTEN 
(phosphatase and tensin homologue deleted on chromosome 1 0 ) as a 
signalling intermediary. PTEN controls signalling molecules critical in 
proliferation and apoptosis such as PKB. S IP 2 regulates PTEN via a Rho 
GTPase dependent mechanism since expression of a RhoA dominant 
negative restored S IP  -induced migration [220]. S IP 2 activity has also been 
shown to diminish PDGF receptor function. Deletion of S IP 2 dramatically 
improved the cells’ migratory capacity toward S IP  and PDGF. S IP 2 null 
MEFs also showed enhanced Rac and SphKI activity [221]. Flowever, 81 Pi 
has a positive role in PDGF-induced migration as expression of the receptor 
appears to be critical for cell motility [2 2 2 ].
81P also induces the rearrangement of focal adhesion complexes by 
stimulating the tyrosine phosphorylation and activation of FAK. 81P was also 
shown to promote a transient association of paxillin (a component of focal 
adhesions) with GITs (G protein-coupled receptor kinase-interacting 
proteins). Both FAK and paxillin co-localise to the cell cortical area 
suggesting role for S IP  in barrier enhancement [223].
1.5.8 The Role of S IP  in Angiogenesis
Angiogenesis is defined as the formation of new blood vessels from 
pre-existing ones. This is a crucial function in development, wound healing 
and pathological events such as cancer [224]. Angiogenesis involves several 
complex steps including ECM degradation, migration, proliferation of 
endothelial cells and their differentiation into capillary-like structures. These 
processes are regulated by growth factors like VEGF and angiopoietin. 
VEGF mediates the production of nitric oxide (NO) via PKB-induced 
phosphorylation of eN 08 [207]. NO production has a crucial role in 
regulation of vascular tone, remodelling and angiogenesis [225]. S IP  also 
induces NO-mediated angiogenesis through the same mechanism [226].
S IP  was ascertained to be a regulator of angiogenesis when it was 
discovered that the receptors 81 Pi and 8 1 P3 were required for the 
endothelial cell morphogenesis into capillary-like tubes by regulating the
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assembly of vascular endothelial adherens junctions [227, 228]. Endothelial 
cells treated with S1P display increased recruitment of ad he re n molecules 
such as VE-cadherin and eaten in a,p and y to the region of cell-cell contact 
[229].
S1P has been demonstrated to be an essential mediator of 
neovascularisation during embryonic development. In fact, deletion of the 
S1Pi in mice by homologous recombination is lethal in utero at E12.5-13.5 
caused by massive haemorrhaging due to incomplete vascular maturation. 
Histological data from the S1Pi mutants show that the endothelial cells form 
vascular networks implying that it is not essential for differentiation, 
proliferation and migration of endothelial cells. The abnormalities can be 
attributed to the failure of VSMCs and pericytes to be recruited to nascent 
vessels. Without the stabilising support of the periendothelium the newly 
formed blood vessel is leaky [230]. As S1Pi is expressed in both endothelial 
cells and VSMCs the question of which cell type mediated vascular 
maturation was still unanswered since VSMC were found in the locality. Mice 
lacking the 81 Pi gene in endothelial cells only were generated using the 
Cre/loxP system and the phenotype mimicked that of embryos that were 
globally deficient in 81 Pi. These data indicate that endothelial cells direct 
VSMCs and expression of 81Pi in these cells is not crucial in the process of 
vascular maturation [231]. In addition, local injection of 81 Pi siRNA into 
established tumours suppressed vascular stabilisation and angiogenesis. 
This resulted in a significant reduction in tumour growth in vivo implicating 
that siRNA technology may provide a valuable therapeutic tool in treating 
cancer [232]. Furthermore, PDGFRp-null mice show similar aberrations to 
81 Pi null mice, i.e. a lack of pericyte recruitment and death at E9.5-12.5 
[233, 234].
8 urprisingly, 8 1 P3 knockout mice have no phenotypic aberrations and 
produce viable offspring although 81P-induced activation of PLC is defective 
in 81p3-null MEFs [235]. The 81 Pg receptor knockouts also produce 
apparently normal mice but again, selective loss of S IP  signal transduction is 
observed but in this instance it is 81P-induced Rho-activation that is impaired 
[236]. Signal transduction in 81 Pi knockout MEFs is also impaired as these 
cells showed an inability to activate Rac [230].
48
It has been established that S1P is an important mediator in vascular 
stabilisation. S1P signalling also enhances endothelial barrier integrity and it 
has been shown to regulate the assembly of cell-cell junctions. S1Pi and 
S1P3 signalling enhances endothelial cell barrier function [229]. In addition to 
this S IP 1 receptor activation has linked to the strengthening of cell-cell 
adhesion by promoting N-cadherin trafficking and activation [237].
S1P signalling has been demonstrated in endothelial remodelling 
through the association of the Arp2/3 complex and cortactin (cortical actin- 
associated protein) as disruption of this interaction impedes S1P-induced 
formation of capillary networks [238]. S1P has also been shown to be a 
potent regulator of lumen formation and morphogenesis on collagen and 
fibrin three-dimensional matrices. Matrix metalloproteinases (MMPs) 
mediate the degradation of ECM proteins and are regulated by tissue 
inhibitors of metalloproteinases (TIMPs) of which there are four isoforms 
(TIMP1-4). TIMP-3 was the only inhibitor that was able to attenuate the S1P- 
induced invasion of cells into three-dimensional matrices [239].
FTY720 is a fungal metabolite that has been demonstrated by clinical 
trials, to be a potent immunosuppressor in de novo renal transplantation 
[240]. It acts by sequestering circulating lymphocytes into secondary 
lymphoid organs, thereby preventing their redistribution to areas of 
inflammation [241]. FTY720 induces an immunosuppressed state that is not 
generalised, and is also reversible [242, 243]. It is phosphorylated in vivo by 
SphK and the resulting metabolite, FTY720 phosphate (FTY720P) bears 
structural similarity to S IP  (Figure 1.16). FTY720P displays a high affinity for 
all the S IP  receptors except S IP 2 , with which it has an equilibrium binding 
constant (K|) of over 1000 [244]. Furthermore, FYT720P has been shown to 
stimulate migration, differentiation and survival in a mode comparable to S IP  
[245].
However, FTY720 has been identified as an antagonist of S I P -  
mediated signalling via S^P^, S I P 2  and S I P 5  at nanomolar concentrations. It 
induces S I P 1  internalisation without stimulating receptor signalling and 
targets the receptor for degradation rather than recycling back to the cell 
surface. Flowever, at present, the mechanism for this phenomenon is 
unknown [246]. In addition to this, FTY720 has been demonstrated to inhibit
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both S1P and VEGF-mediated angiogenesis and block tumour progression in 
vivo. Thus, functional antagonism of the S1P receptors by this molecule may 
provide a new therapeutic approach to dysfunctional regulation of 
angiogenesis in cancerous tumours [247].
Prior to establishing a vascular network in order to grow, the 
cancerous cell must bypass the intrinsic cell suicide mechanisms triggered by 
aberrant growth patterns. Understanding dysfunction of apoptosis, the 
body’s method of removing damaged, infected and superfluous cells is 
another vital avenue for research into cancer therapeutics [248].
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Figure 1.11 The Rho-like GTPase Cycle
Rho-like proteins such as Rac cycle between an inactive GDP-bound 
state and an active GTP-bound state. Transitions between the two are 
controlled by GEFs (guanine nucleotide exchange factors), GAPs (GTPase- 
activating proteins) and GDIs (GDP dissociation inhibitors). GEFs also select 
downstream effectors either directly or via interaction with scaffold proteins.
51
GTP
Effectors
I
Cytoskeletal
Changes
52
Figure 1.12 The-Ilke Rho GTPase Family
Phylogenetic tree representing the twenty members of the Rho 
GTPase family (taken from Burridge et af) [249].
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Figure 1.13 The Rho-like GTPases Regulate Cell Migration
An illustration of a migrating cell; Cdc42 regulates the direction of 
movement, Rac induces membrane protrusion at the leading edge through 
promotion of actin polymerisation and integrin adhesion complexes. Rho 
promotes actin-myosin mediated contraction and cell rounding. All these 
actions must be co-ordinated in space and time to result in a net forward 
movement [162].
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1. Direction of movement (Cdc42)
4.Contractlon (Rho)
2. Lamelllpodial 
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Figure 1.14 Signalling Pathways of Cytoskeletai Dynamics
Rho mediates actin-myosin assembly through mDIa and ROCK. 
ROCK is known to phosphorylate LIMK which results in phosphorylation of 
cofilin and myosin light chain phosphatase encouraging MLC phosphorylation 
and actin-myosin crosslinking. Rac and Cdc42 regulate actin polymerisation 
via the WASpAA/AVE proteins which act on Arp2/3 complex and also through 
p65PAK activating LIM kinase (adapted from Raftopoulou and Hall) [162].
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Figure 1.15 S I Pi Activates Rac In a PKB-Dependent Manner
The model proposed by Lee et al [126] suggests that transactivation of 
S1Pi by PKB is essential for S1Pi-mediated Rac activation. S IP  binds to 
81 Pi results in PI 3-kinase mediated translocation of PKB to the plasma 
membrane. PKB is activated by the phosphorylation at Ser473 and Thr308. 
This results in an increased association of PKB with the third intracellular 
loop of 81 Pi which leads to the PKB-mediated phosphorylation of Thr236. 
This action is required for the Rac activation and subsequent actin assembly.
PDK= 3-phosphoinositide-dependent kinase
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Figure 1.16 The Compound FTY720P is Structuraiiy Similar to S IP
FTY720 is a weak agonist for the 81P receptors but addition of the 
phosphate ester group to yield FTY720P increases the potency by a 1000 
fold. FTY720P acts on 81 Pi, 8 IP 3, 8 IP 4 and 8 IP 5 receptors but not 8 IP 2 
(image taken from Rosen and Liao) [250].
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1.6 Morphological features of Apoptosis
Apoptosis (or active cell death) can be defined as a form of cell death 
In which a well ordered sequence of events leads to the elimination of the cell 
without releasing harmful substances into the surrounding area [251]. In 
contrast to apoptosis, the other form of cell death, necrosis (or passive cell 
death) is characterised by progressive loss plasma membrane integrity and 
influx of N a \ Ca^^ and H2O [252, 253]. This causes cytoplasmic swelling 
and eventually the plasma membrane will rupture releasing the lysosomal 
and granular contents of the cell into the extracellular space causing an 
inflammatory response [254]. The word apoptosis is derived from Greek and 
alludes to the dropping of leaves from a tree [255]. The morphological 
features of apoptosis include:
• blebbing of plasma membrane,
• chromatin condensation,
• nuclear fragmentation,
• loss of adhesion and cell shrinkage [255, 256]
The biochemical features of apoptosis include:
• internucleosomal cleavage of DNA resulting in an oligonucleosomal 
ladder [257],
• phosphatidylserine (PS) externalisation [258],
• proteolytic cleavage of intracellular substrates [259].
The dying cell fragments into apoptotic bodies which are recognised by 
neighbouring cells and consequently phagocytosed. Programmed cell death 
has a distinct morphology and the mechanism of cell dismantlement is the 
same regardless of the stimulus that initiated the process [260].
1.6.1 The Bcl-2 Family
The Bcl-2 family of proteins constitutes a critical intracellular 
checkpoint in the intrinsic cell death pathway. The prototypic member, Bcl-2 
was first identified as a proto-oncogene in B cell lymphoma [261]. It was 
subsequently identified as the mammalian homologue of ced-9 which has an 
pro-survival role in C.elegans [262]. There are 19 members identified to 
date, each of which contains at least one of the four conserved domains Bcl-
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2 homology domains (BH1-4). The Bcl-2 family can be divided into three 
categories:
1. Anti-apoptotic proteins; Bcl-2, BcI-Xl, BcI-w (BH1-4), Mcl-1, A1, NR-13 
and Boo (contain at least BH1 & 2, those most similar to Bcl-2 have 
BH1-4),
2. Pro-apoptotic proteins; Bax, Bak and Bok (BH1-3, also known as 
multi-domain proteins),
3. Pro-apoptotic ‘BH3-only’ proteins; Bid, Bad, Bim, Bik, BIk, Hrk, Bnip3, 
Puma and Noxa (Figure 1.17) [248, 263, 264].
The caspase cascade is regulated by the Bcl-2 family of proteins. Anti- 
apoptotic Bcl-2 proteins reside in the mitochondrial outer membrane to 
protect mitochondrial integrity and prevent cytochrome c release by binding 
and sequestering pro-apoptotic BH3-only proteins, thus preventing Bax and 
Bak activation [265].
Bim, Bid and Puma are termed as activators of Bax and Bad and pro­
survival Bcl-2 proteins act to divert these molecules’ activity, whereas other 
BH3 proteins like Bad and Noxa do not have the ability to activate Bax 
directly and are described as sensitizers or depressors [266]. Apoptosis is 
initiated by BH3-only proteins, which are stringently regulated by 
transcriptional and/or post-transcriptional controls. In particular relevance to 
this thesis, the BH3-only protein Bim is believed to have a prominent role in 
apoptosis caused by removal of trophic factors [267, 268].
1.6.2 The BH3-only protein Bim
The Bim (Bcl-2 interacting mediator of cell death) locus encodes three 
isoforms: Bims (Bim short), B\rr\i (Bim long) and Bimei (Bim extra long) which 
is the most abundant isoform. Recently, it has been predicted that there may 
be up to eighteen splice variants [269]. However, these variant gene 
products have not been detected endogenously [267]. All three major 
isoforms are potent inducers of apoptosis although Bims is the most cytotoxic 
[270]. Bim is expressed de novo following the withdrawal of survival factors 
in various cell types including haematopoietic cells [271], neurons [272], 
osteoclasts [273] and fibroblasts [274].
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Bim activity can be regulated by phosphorylation of BimEL by ERK1/2. 
This antagonises the ability of Bim to induce apoptosis in response to loss of 
trophic factors by promoting its proteosomal-mediated degradation following 
poly-ubiquitylation. [274, 275]. The ERK-mediated phosphorylation of BimEL 
also protect cells from apoptosis by preventing its interaction with Bax [276].
Another way in which Bimi and BimEi activity is regulated is 
interaction with microtubule complexes by binding to dynein light chain 
(DLC1) which is a component of the dynein motor complex. Growth factor 
deprivation and other apoptotic stimuli result in the release of Bim-DLC1 
complex and its translocation to mitochondria where it is activated neutralises 
the anti-apoptotic effects of Bcl-2 proteins [277]. The stress-activated kinase 
JNK has been shown to phosphorylate Bimt on Thr56, which is located within 
the DLC1 binding-motif and can also phosphorylate either Ser44 or Ser58 
residues. This disrupts the BimL-DLC1 complex which facilitates its release 
thereby promoting cytochrome c release and activation of downstream cell 
death machinery [278].
1.6.3 The Caspase Family
The cellular machinery for apoptosis is well conserved in all 
multicellular organisms [264]. Caspases (cysteinyl aspartate-specific 
proteinases) mediate very specific proteolytic events in apoptotic cells [279]. 
The role of caspases in cell death was discovered when genetic analysis of 
C.elegans revealed the genes ced-3, -4 and -9 are crucial in apoptotic 
processes during development [280]. The discovery that ced-3 has 
sequence homology to a mammalian cysteine protease called interleukinip- 
converting enzyme (ICE/caspase-1) [281] led to the search for other 
mammalian homologues. Caspase-3 was found to have the most similar 
substrate preferences [282]. To date there are fourteen mammalian 
caspases known, eleven of which are human. The caspase family at present 
is divided into ICE-like or CED-like categories (Figure 1.18).
Caspases exist as zymogens and a have similar structural 
organisation and substrate specificity [279]. They each contain three
domains:
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• N-terminal pro-domain (N-peptide)
• large subunit containing the active site cysteine within a conserved,
QACXG motif (17-20 kDa),
• C-terminal small subunit (9-12 kDa).
Caspases are activated by two cleavage events; the first divides the large 
and small subunits leaving a second that separates the N-peptide from the 
large subunit. The active enzyme Is a tetramer containing two large and two 
small subunits [260].
Caspases are grouped according to pro-domain length into initiator 
caspases or effector caspases. Long pro-domain caspases (such as 
capases-2,-8,-9 and -10) are recruited by adaptor proteins into membrane 
receptor complexes so therefore function to initiate the effector caspases i.e. 
those with short pro-domains (such as caspases-3,-6 and -7) [283].
1.6.4 Inhibitors of Caspases
Protease activity is crucial throughout the life of the cell but in order to 
control their destructive abilities this group of enzymes requires careful 
regulation. As well as being expressed as zymogens caspases have another 
level of negative regulation placed upon them -  namely inhibitors of 
apoptosis (lAPs) which function to inhibit inappropriate cell death. There are 
five lAPs identified in mammals: X-linked inhibitor of apoptosis (X-IAP), c- 
IAP1, C-IAP2, neuronal lAP and survivin [263]. X-IAP displays the most 
extensive and robust activity, and alongside C-IAP1 and C-IAP2 can directly 
inhibit caspase activity by binding and inactivating caspases-3,-7 and-9 but 
not caspases-1, -6 , - 8  o r -10 [284, 285].
The binding of lAPs to caspases is mediated via the baculovirus lAP 
repeats (BIR) which each consist of approximately seventy amino acids
[286]. Within each lAP there are three tandem copies of the BIR domain 
(BIR1-3), one of which (BIR2) is required for inhibition of caspase activity
[287]. Furthermore, there is a RING domain within each lAP at the C- 
terminal which displays E3 ubiquitin ligase activity by binding E2 ubiquitin- 
conjugating enzyme and so catalysing the recruitment of ubiquitin. Thereby 
the lAP is functioning to promote both its own proteosomal-mediated 
degradation and any caspase to which it is bound [288, 289]. c-IAPI and c-
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IAP2 each contain caspase recruitment domains (CARD) [290] which implies 
they may also function in the regulation of caspase processing and 
activation.
The activity of caspases may also be attenuated by additional class of 
Inhibitor termed pseudocaspases which evolved by gene duplication. 
Pseudocaspases lack protease activity and inhibit caspase activation by 
interaction with caspase activation complexes [283]. For example, FLICE 
(Fas-associated death domain protein-like interleukin-1 p-converting enzyme) 
binds to the death effector domain (DED) of FADD thereby inducing 
apoptosis [291]. c-FLIP (FLICE-like inhibitory protein) is a catalytically 
inactive caspase-8 / - 1 0  homologue which competes with caspase- 8  for 
binding to FADD at the cytoplasmic face of the Fas receptor, thereby 
attenuating activation of the caspase cascade [292]. The various stimuli that 
can trigger a cell's apoptotic machinery can be divided into extrinsic 
(receptor-mediated) or intrinsic (non-receptor-mediated) pathways. Despite 
the variety of factors able to induce apoptosis, these all converge at the 
mitochondria and the release of cytochrome c [283].
1.6.5 The Extrinsic Pathway of Apoptosis
Extrinsic apoptosis is driven by the activation of death receptors 
belonging to the TNF receptor family (TNFR) including Fas/CD95, DR3, and 
DR4/TRA1L. These receptors each contain an intracellular amino acid 
stretch in the C-terminus called the death domain (DD) [293], which is 
responsible for activation of the caspase cascade which ultimately ends in 
the cell undergoing apoptosis. For instance. Fas associates with the adaptor 
protein Fas-associated death domain protein (FADD) via a DD-DD 
interaction. Fas-bound FADD can then associate with pro-caspase- 8  through 
another functional domain called the death effector domain (DED). The 
aggregation of two or more pro-casapse- 8  molecules enables them to 
process one another Into their active form, thereby triggering the caspase 
cascade [263, 294].
Activated caspase- 8  not only cleaves caspase-3 but can further 
amplify the apoptotic signal by causing mitochondrial injury via the cleavage 
and release of the pro-apoptotic C-terminal fragment of the BH3-oniy protein
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Bid (tBid). tBid then serves as a membrane-targeted ligand that triggers the 
oligomerisation of Bax or Bak resulting in cytochrome c release [295].
Another set of death receptors (DR4/5) share a different death ligand 
known as TRAIL (TNF-related Apoptosis Inducing Ligand) [296, 297]. In 
healthy cells Bim is sequestered by the Bcl-2 protein Mcl-1 but TRAIL- 
mediated activation of granzyme B (a serine protease) or caspase-3 causes 
the degradation of Mcl-1. This allows the liberated Bim to activate Bax which 
leads to cytochrome c release thereby further propagating the apoptotic 
signal [298].
1.6.6 The Intrinsic Pathway of Apoptosis
Intrinsic cell death is mediated by the release of cytochrome cfrom the 
mitochondria. Stimuli that can provoke apoptosis by this route include 
cytotoxic drugs, radiation, heat shock and, of relevance to this thesis, the 
removal of trophic factors [299]. This serves to initiate the caspase cascade 
in a similar mechanism to death receptors.
DNA damage can initiate apoptosis if not repaired by checkpoint 
genes [300]. Up-regulation of p53 caused by DNA damage results in the 
transcription of Bax and its subsequent translocation to the mitochondria 
[301]. Bax and Bak exist as monomers in viable cells and it is believed upon 
receipt of a pro-apoptotic signal they form homo-oligomers that insert into the 
mitochondrial membrane. This causes the formation of pores resulting in the 
release of cytochrome c [295]. DNA damage also results in the up-regulation 
of the BH3-only proteins Bax, Noxa and Puma driven by the checkpoint 
kinases CHK1 and 2 activation and p73 up-regulation [302].
Pro-apoptotic BH3-only proteins are localised in the cytosol and can 
induce apoptosis in two ways: inactivation of anti-apoptotic Bcl-2-like proteins 
by direct binding or by modification of Bax-like proteins. For example. Bad 
function is believed to be modulated by phosphorylation. Phosphorylation of 
Bad in response to survival factor signalling promotes its sequestration by 
14-3-3, however de-phosphorylation of Bad leaves it free to act as an 
antagonist to anti-apoptotic Bcl-2 proteins [209, 303]. Both Bad and Bid are 
substrates of caspases, and truncation of these proteins results in their
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translocation to the mitochondria and the promotion of cytochrome c release 
[295, 304].
A second protein with the ability to activate caspases [Smac (second 
mitochondria-derived activator of caspases)/DIABLO (direct lAP binding 
protein with low pi)] was discovered to be released at the same time as 
cytochrome c. Smac/DIABLO eliminates the inhibitory effect of many lAPs 
including X-IAP, c-IAP-1, c-IAP-2 and survivin [305, 306]. Studies of its 
crystal structure show Smac/DIABLO to be complexed with the BIR3 domain 
which primarily targets pro-capase-9 [287, 307, 308], thus allowing the 
activation of pro-caspase-9 and the caspase cascade.
1.6.7 Apaf-1 and the Apoptosome
Cytochrome c release is an early event in apoptosis and regardless of 
the initial stimulus all mitochondria release cytochrome c within 
approximately 5 minutes [263]. Cytochrome c then binds to Apaf-1 (apoptotic 
protease activating factor) via its WD40 domain. Apaf-1 is the mammalian 
homologue of the aforementioned ced-4 [309]. Apaf-1 then promotes the 
clustering of pro-caspase-9 and in association with ATP causes a 
conformational change facilitating heptamer assembly in the shape of a 
wheel called the ‘apoptosome’ [310, 311]. This is comprised of several Apaf- 
1 molecules each bound to a molecule of caspase-9 via their caspase- 
recruitment domains (CARD) which causes the proximity-induced activation 
of caspase-9 [312]. Caspase-9 cleaves and activates both caspase-3 and -7. 
Caspase-3 then drives the activation of caspase-2 and - 6  leading to the 
activation of caspases- 8  and -10 (Figure 1.19) [313].
The executioner caspases (-3, -6 , and -7 ) have a varied range of 
substrates including structural proteins, signalling proteins and regulators of 
DNA replication and transcription (Table 1.3). These include Bcl-2 and Bcl- 
X l which are cleaved by caspase-3 thereby destroying their protective 
function by revealing the C-terminal fragments which are pro-apoptotic [260, 
314].
As the signal propagates other components of the apoptotic 
machinery are activated. CAD (caspase-activated deoxyribonuclease) exists 
in an inactive state bound to its inhibitor iCAD which acts as a specific
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chaperone during its synthesis. Caspase-3 action cleaves iCAD causing the 
dissociation allowing CAD to enter the nucleus and display DNase activity 
thereby leading to DNA fragmentation [315]. The DNA repair enzyme poly 
(ADP-ribose) polymerase (PARP), which catalyses the addition of ADP- 
ribose to nuclear proteins such as histones, is also cleaved by caspase-3 
[316, 317].
Caspase activity also functions in the destruction of the nuclear 
envelope by cleavage of lamins which leads to nuclear shrinkage and 
contributes to chromatin condensation. Lamins are arranged in head-to tail 
polymers of intermediate filaments which is cleaved at a single site by 
caspases [318-320]. Loss of adherence and overall cell shape (blebbing) is 
caused by the cleavage of proteins that regulate the cytoskeleton such as 
fodrin [321], gelosin [322] and FAK [323]. In addition, caspase-mediated 
cleavage of p21-activated kinase (PAK2) contributes to the formation of 
apoptotic bodies [324, 325].
1.6.8 The Role of SphK in Cell Survival
Ceramide and sphingosine are known inducers of apoptosis whereas 
SphK activation and concomitant 81P production is associated with growth 
and survival [77]. It has been proposed that it is not absolute amounts of 
ceramide/sphingosine to S IP  but the proportion of each that determines cell 
fate. This is known as the “sphingolipid rheostat” model [78].
Nevertheless, there Is increasing body of evidence that suggests that 
SphK1 and 2 may have opposing roles in determining cell fate [326, 327]. 
SphK1 stimulates growth and proliferation, promotes Gi-S transition and 
protects cells from serum deprivation- and ceramide-induced apoptosis [328]. 
Activation of SphKI in HUVECs by TNFa and subsequent production of S IP  
has also been shown to protect cells from TNFa-induced apoptosis [92]. The 
mechanism for this protection is thought to be via the activation of SphKI by 
TNFa receptor-associated factors (TRAFs). Within SphKI there is a TRAF- 
2-binding motif that mediates this interaction. This is required for the TRAF- 
2-induced activation of the anti-apoptotic transcription factor NF-kB but not 
for JNK [329]. In addition to this, S IP  has been implicated in the up-
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regulation of another anti-apoptotic transcription factor, activator protein- 1 
(AP-1) [330].
There are several mechanisms by which intracellular S1P is thought to 
act to prevent programmed cell death. In a A-375 melanoma cell line the 
over-expression of the pro-survival protein Bcl-2 markedly increased SphKI 
expression and activity and this conferred protection from Fas- and 
ceramide-mediated apoptosis [94]. In Jurkat cells, S1P has been shown to 
inactivate the BH3-only molecule Bad via the ERK pathway and to also 
obstruct the translocation of Bax to the mitochondria, thereby preventing the 
release of cytochrome c. This action could not be attributed to S1P binding 
its receptors as concentrations of <50nM did not confer cytoprefection [331]. 
Moreover, the S IP  analogue sphingosine-1 -phosphonate, which does not 
bind to S IP  receptors, inhibited apoptosis in these cells [332]. In addition, 
over-expression of SphKI has been associated with the down-regulation of 
the pro-apoptotic protein Bim in endothelial cells [333].
In contrast to SphKI, SphK2 has been associated with suppression of 
proliferation and induction of apoptosis [334]. SphK2 contains a nine amino 
acid motif that is similar to the BH3 domain found in pro-apoptotic BFI3-only 
proteins [335, 336]. However, mutation of conserved leucine residues in the 
BH3 domain did not abolish SphK2-induced apoptosis, indicating that there 
may be other factors involved [335]. In contrast to initial studies, it has been 
demonstrated in various cells types that SphK2 activity Is localised to the 
nucleus where its activity has been shown to inhibit DNA synthesis. SphK2 
localisation to the nucleus appears to be essential for this action although no 
substrate has been identified [95].
The pro-apoptotic actions of SphK2 appear to be independent of cell 
surface receptors S IP 1.3 . Attenuation of S IP 1 signalling by treatment with 
pertussis toxin was shown to have no effect SphK2-induced apoptosis. Also, 
the utilisation mouse embryonic fibroblasts (MEFs) lacking S IP 2 , S IP 3 or 
both had no effect on the ability of SphK2 to induce apoptosis [335]. Another 
study using the neuronal cell line PC 12 showed that SphKI over-expression 
prevents serum withdrawal-induced apoptosis in a GHndependent manner. 
Cell death is averted by the inhibition of the JNK pathway and the 
executioner caspases 2, 3 and 7 [337]. Since SphKI activation and
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translocation is associated with secretion of S1P it is very difficult to 
differentiate any intracellular actions from receptor-mediated responses [96].
1.6.9 The Role of S IP  Receptors in Cell Survival
Although there are many studies examining a role for 81P signalling 
intracellularly, no intracellular target has been identified in higher eukaryotes. 
The intracellular level of S IP  in HUVECs is relatively low whereas activated 
platelets are an abundant source of SIP. It has been proposed that S IP  
acts as a survival factor for endothelial cells and that platelets assist in the 
maintenance of endothelial cell integrity by making and releasing S IP  which 
binds and activates cell surface S IP  receptors [338], Extracellular S IP  is 
found mainly in circulating lipoproteins in the order of high density 
lipoproteins (HDL)>low density lipoproteins (LDL)>very low density 
lipoproteins (VLDL) [339]. The mild oxidation of LDLs is characteristic of the 
onset of atherosclerosis [340]. The level of S IP  present in LDLs is 
approximately four times lower than in HDLs [341]. Furthermore, the 
oxidative modification of LDL (ox-LDL) further reduces the content of S IP  
and reduces their affinity for each other [342]. Both S1P and HDL protect 
endothelial cells from serum deprivation and ox-LDL [343, 344]. The binding 
of S IP  to plasma components is believed to regulate its ability to interact with 
cell surface receptors [339]. Lipoprotein delivery of S IP  to its receptors may 
offer an explanation why higher doses of S IP  are required to elicit receptor- 
mediated responses in vitro than occur naturally in the circulation [345].
Indeed the extensively documented protective effect of HDLs in 
vasculature is now thought to be due to their bioactive lipid element. HDL 
binds to the scavenger receptor type 1 (SR-B1) on endothelial cells and 
stimulates NO release via activation of endothelial NO synthase (eNOS) 
[346, 347]. However the component known to bind SR-B1 apolipoprotein A1 
(apoAl) does not activate eNOS [347]. A further study revealed that S IP 3 
receptor activation was required for NO production and release. This 
indicates that HDL is acting as a carrier for S1P, bringing it in close enough 
proximity to bind S1P receptor(s) [348].
NO can promote either survival or apoptosis depending on 
concentration and cell type [349], NO is produced by enzymatic oxidation of
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L~arginine by nitric oxide synthase (NOS) and subsequently binds to guanylyl 
cyclase (GC)-coupled receptors which trigger the production of guanosine 3’, 
5’ monophosphate (cGMP) from GTP [350]. cGMP interacts with various 
downstream targets such as cGMP dependent kinases, phosphodiesterases 
(PDEs) and ion channels [350]. NO also confers protection against the pro- 
apoptotic effects of TNFa via cGMP-mediated activation of protein kinase G 
and the inhibition sphingomyelinase. However, this mechanism of protection 
operates during the early stages of apoptosis [351]. Another cGMP 
dependent effect is believed to be inhibition of the release of cytochrome c 
from the mitochondria via the up-regulation of Bcl-2 proteins and the down- 
regulation of the adaptor protein p6 6 ®*^'^  [352].
NO also inhibits apoptosis independently of cGMP by the post- 
translational modification of caspases. One such modification is S- 
nitrosylation (addition of NO) to the thiol group of the cysteine residue in the 
active site which is conserved in all caspases [353-355]. In addition to this, 
NO is believed to interfere with the assembly of the apoptosome complex by 
inhibiting interaction between Apaf-1 and pro-caspase-9 via their CARD 
domains. Consequently this attenuates the sequential activation of 
caspases-9, -3 and - 8  which are required for programmed cell death [356]. 
Furthermore, endothelial cells in particular, undergo a specific type of 
apoptosis in response to reactive oxygen species (ROS)-mediated 
endothelial injury called anoikis (a type of cell death induced by the loss of 
cell-matrix interactions) [357]. NO acts as an anti-oxidant mopping up ROS 
generated by ceramide thereby preventing programmed cell death by DNA 
damage [358].
In endothelial cells NO production has cytoprotective effects [358]. 
eNOS is constitutively expressed in endothelial cells and is localised in 
caveolae through association with caveolin-1. There is evidence that S1Pi is 
targeted to caveolae upon agonist stimulation [359]. It has also been 
suggested that S1Pi may facilitate eNOS activation by allowing its release 
from caveolin-1 [360]. Stimulation of SI Pi has also been shown to activate 
eNOS via the serine/threonine kinase PKB which phosphorylates eNOS on 
serine 1177 [207, 361]. VEGF has also been identified as an activator of
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eNOS through the same pathway via the Flk-1 receptor. S1P is believed to 
augment this action by increasing the tyrosine phosphorylation of Flk-1 [362].
In addition to this, S1Pi signalling is also thought to enhance Ca^^ 
sensitive NOS activity in endothelial cells. This was demonstrated using anti­
sense oligonucleotides against S1Pi which significantly reduced S1P- 
induced protection from serum withdrawal. Anti-sense S I P 3  oligonucleotides 
partially reduced this effect. NO production was suppressed by treatment 
with pertussis toxin, the PLC inhibitor U73122 and the Ca^^ chelator BAPTA- 
AM. The inhibition of caspase-3 activity was also observed [344].
S I P 2  and S I P 3  have been shown not only to confer protection from 
serum withdrawal but stimulate cell proliferation by activating ERK in HTC4 
hepatoma cells. The transient induction of the AP-1 transcription factors c- 
Jun and c-Fos leading to that activation of c-/bs and serum response element 
was observed [363]. Another study in HEK cells suggests a role for S I P 2  
and S I P 3  but not S I P 1  in the activation of NFkB. This action is thought to be 
mediated by Gq or G13 and requires PKC and Ca^^ to activate NFkB [364]. 
NFkB up-regulates the transcription of many survival factors including, 
TRAF-1, -2, Bcl-2 and cellular inhibitors of apoptosis proteins (clAPs) [365]. 
S I P  production also protects against TNFa-induced cell death in hepatocytes 
by activation of the PI3K/PKB pathway [366]. The S I P 1 . 3  receptors are 
known to activate this pathway. One of the downstream targets of PKB is the 
pro-apoptotic protein Bad and the subsequent phosphorylation attenuates 
Bad activity [209].
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Figure 1.17 The Bcl-2 Family
There are three subfamilies within the Bcl-2 family: anti-apoptotic Bcl-2 
family member promote cell survival (the members with the most homology 
to Bcl-2 contain all four BH domains), pro-apoptotic and BH3-only proteins 
promote cell death. Bid and Bad do not contain a membrane-anchoring 
domain [263].
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Figure 1.18 The Caspase Family
The caspase family divides into two major phylogénie sub-families 
(ICE and CED-3). They can be further segregated based on their substrate 
specificity; inflammatory caspases which regulate cytokine maturation (red), 
effectors of apoptosis (blue) or initiators of apoptosis (green) (adapted from 
Zimmermann et al) [263].
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Figure 1.19 Apaf and the Apoptosome
Despite the variety of insult on the cell the various pathways of 
apoptosis converge at the mitochondria where cytochrome c release causes 
the clustering of pro-caspase-9 and Apaf-1. The subsequent activation of 
caspase-9 and caspase-3 initiates the caspase cascade. Caspase-3 can 
also activate upstream caspases such as caspase- 8  which further amplifies 
the pro-apoptotic signal. The proteolysis of cell and nuclear components 
ultimately results in apoptosis.
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Table 1.3 Caspase Substrates
Substrate Class Function Examples
Pro- and anti-apoptotic 
proteins
Signal amplification 
Inactivation o f 
apoptotic inhibitors
Components of apoptotic inducing the apoptotic
machinery phenotype
Structural proteins
Homeostatic proteins
Dissolution of cell 
integrity
Cellular packaging
Disruption of 
macromoiecular 
synthesis and cellular 
repair mechanisms
Pro-caspases
Bcl-2
BcI-Xl
Bid
ICAD
Gelosin
PAK2
MEKK1
PKCÔ
Lamins
Fodrin
Keratins
Actin
Catenins
FAK
DNA-PKca
PARP
HnRNPs
Transcription factors
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Aims
The bioactive lipid sphingosine-1-phosphate is recognised as a 
mediator of cell processes such as small G protein activation and cell survival 
through the receptor S1Pi, but the mechanisms involved are not yet fully 
understood. Therefore the aim of this PhD is to further characterise aspects 
of S 1 Pi receptor regulation and signal transduction with respect to control of 
cytoskeletal dynamics and cell survival.
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Chapter 2 
Materials and Methods
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2.1 Materials
Abeam Ltd., Cambridge, UK
Anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody (cat # 
ab8243, used at 1:20,000)
Affinity Bio Reagents, Colorado, USA
S1Pi antibody (cat # PA1-1040 used at a 5jag/ml)
Amersham Biosciences, Golden, CO, USA
p P ] orthophosphate (10mCi/ml), glutathione-Sepharose beads
Biorad, Laboratories Inc., Herts UK
Protein assay dye reagent concentrate
BDH-MERCK, Chemicals Ltd., Poole, UK
Ammonium persulphate, sodium dodecyl sulphate, sodium chloride, 
vitronectin
Calbiochem-Novabiochem, Nottingham, UK
D-ef/?ym-sphingosine-1-phosphate (SIP), LY294002, U0126, GF109203X, L- 
fhreo-dihydrosphingosine (DHS), dihydrochloride (emetine)
Cell Signalling Technology, Beverly, MA, USA
Anti-ERK antibody (cat # 9102, used at 1:1000), anti- phospho 
(Tyr202/Tyr204) ERK antibody (cat # 9106, used at 1:1000), anti-cleaved 
caspase-3 (Asp 175) antibody (cat # 9661, used at 1:500), anti-phospho 
(Ser473) PKB antibody (cat # 9271, used at 1:1000)
Chemicon International, USA
Caspase-3 Colorimetric Activity Assay Kit, anti-Bim antibody (cat # AB17003, 
used at 1 :1 0 0 0 )
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Duchefa Biochemîe, Haarlem, Netherlands
Yeast extract, tryptone, microagar
Eurogentec, Belgium
9E10 ascites fluid (used at 1:1000)
Fisher Scientific, Loughborough, Leicestershire, UK
Glycine, 4-2-hydroxyethyl-1- piperazineethanesulphonic acid (HEPES), 
ethylenediaminetetra-acetic acid (EDTA), dimethyl sulfoxide (DMSO), glacial 
acetic acid, methanol, ethanol, concentrated hydrochloric acid, sodium 
hydroxide, hydroxymethyl-aminomethane (TRIS) base, sodium carbonate, 
sodium hydrogen carbonate, sodium dihydrogen ortho-phosphate, disodium 
hydrogen ortho-phosphate
GiBCO BRL Life Technologies, Paisley, UK
Phosphate-free Dulbecco's Modified Eagle Medium (PFDMEM), cell culture 
grade phosphate-buffered saline (PBS), Optimem, Lipofectamine
Inverclyde Biologicals, Strathclyde Business Park, Bellshill, 
Lanarkshire, UK
Protran nitrocellulose Schleicher and Schuell membrane (0.2|Lim pore size)
Invitrogen Molecular Probes, Inchinnan Business Park, Paisley, UK
Alexa fluor 594-conjugated phalloidin, Alexa Fluor 594-conjugated goat anti­
rabbit (cat # A5163, used at 1:200), Alexa Fluor 488-conjugated goat anti­
rabbit (cat # A31628, used at 1:200)
Melford Laboratories, Chelsworth, Ipswich, Suffolk, UK
Dithiothreitol (DTT), isopropyl-p-D-thiogalactopyranoside (IPTG)
New England Biolabs Inc., Beverly, MA, USA
Rainbow markers (ranging from 6.5-175kD)
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Perkin Elmer Life Sciences, Monza, Italy
Enhanced chemiluminescence (ECL) reagents 
Pierce, Rockford, IL, USA
EZ-link™Biotin-LC-hydrazide, western blot stripping solution 
Promega, Southampton, UK
G-418 sulphate, Promega™ Wizard Plus SV miniprep kit
Riedel-de Haen, Seezle, Germany
Glycerol, calcium chloride
Santa Cruz, California, USA
Anti-Cdc42 antibody (cat # sc6083, used at 1:500)
Sigma-Aldrich Company Ltd., Poole, Dorset, UK
Horseradish peroxidase (HRP)-conjugated anti-mouse (ca t#  A4416, used at 
1:1000) and rabbit IgG (cat # A8275, used at 1:1000) MRP-conjugated 
streptavidin, HRP-conjugated anti-sheep antibody (cat # A3415, used at 
1:1000), rabbit anti-mouse bridging antibody (cat # S1265, used at 1:1000), 
anti-Rac antibody (cat# R2650, used at 1:1000), 30% (w/v) acryiamide/0.8% 
(w/v) bis-acrylamide, Triton X-100, soybean trypsin inhibitor, benzamidine, 
bovine serum albumin (BSA), protein A-Sepharose, sodium fluoride, sodium 
periodate, thimerosal, bromophenol blue, Coomassie Brilliant Blue R-250, 
bichinchonic acid (BOA), ampicillin, N,N,N',N'-tetramethylethylenediamine 
(TEMED), phenyl methyl sulphonyl fluoride (PMSF), Dulbecco’s Modified 
Eagle Medium (DMEM), foetal bovine serum (FBS), cell culture grade trypsin 
(0.5g/L), penicillin/streptomycin, L-glutamine, fibronectin, colchicine, 
cytochalasin B, pertussis toxin, sodium potassium tartrate, deoxycholic acid 
sodium salt, Tween-20, copper (II) sulphate, hydroxypropyl-p-cyclodextrin, 
paraformaldehyde
Universal Biologicals Ltd., Cambridge, UK
Anti-Cdc42 antibody (cat# ACD02, used at 1:500)
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FTY720P (compound 433) was a gift from Dr. Richard Munford, Merck Sharp 
& Dohme, Rahway, New Jersey, USA
PGEX/PAKCRIB construct was a gift from Dr. Steve Yarwood, IBLS, 
Glasgow, UK
PRK5mycL61Rac1 construct was donated from Prof. Alan Hall, UCL,
London, UK
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2.2 Cell Culture
Parental CCL39 (Chinese hamster lung fibroblasts) cells were 
maintained in DMEM supplemented with 10% (v/v) FBS, streptomycin 
(lOOpg/ml), penicillin (lOOunits/m!) and 2mM L-glutamine, which will 
hereafter be referred to as "complete DMEM”. CGL39 cells stably expressing 
the human myc epitope-tagged S1Pi receptor were also maintained in 
complete DMEM further supplemented with G-418 sulphate (I.Gmg/ml) [367]. 
Control CCL39 cells which also have antibiotic resistance were maintained in 
complete DMEM supplemented the same concentration of G418 sulphate. 
All cells were kept at 37°C, in a humidified atmosphere containing 5% (v/v) 
COg. To split the cells, confluent monolayers were washed with tissue 
culture grade PBS, 2ml of trypsin was added and the cells were allowed to 
detach from the flask. 6 ml of the appropriate complete DMEM was added to 
neutralise the trypsin and wash any remaining cells off the flask. This mix 
was gently pipetted to resuspend cells, which were either seeded into dishes 
for experiments or passaged into flasks to maintain the cell line.
2.2.1 Transfection of cells with Lipofectamine
The following transfection method is based on cells cultured in a 6 -well 
dish, in a sterile microfuge tube 120|il of Optimem and 2pg of DNA were 
gently mixed/well to be transfected. In another microfuge tube 120|llI of 
Optimem and 4pl of Lipofectamine transfection reagent was added and 
mixed gently. To this, the DNA/Optimem mix was added and gently mixed. 
This was left to incubate at room temperature in the dark for 45 minutes. The 
cell monolayers were washed briefly with 2ml of Optimem which was 
replaced by 760pl of Optimem. The DNA-lipofectamine mix was then added 
dropwise to each well and placed into the incubator for 3 hours. The 
transfection mix was removed and the medium replaced with complete 
DMEM.
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2.3 Molecular Biology Techniques
2.3.1 Preparation of Antibiotic Agar Plates
LB agar (1% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 1% (w/v) 
sodium chloride and 1.5% (w/v) agar) was prepared, autoclaved and left to 
cool to approximately 37°C before addition of ampicillin at a final 
concentration of 50pg/ml. The liquid LB agar was poured into 10cm Petri 
dishes, allowed to solidify and then left overnight at room temperature to 
allow excess moisture to evaporate. The plates were stored at 4°C for a 
maximum of 4 weeks.
2.3.2 Preparation of Piasmid DNA
10ml of LB broth (1% (w/v) bactotryptone, 0.5% (w/v) yeast extract 
and 1 % (w/v) sodium chloride) supplemented with ampicillin at a 
concentration of 50|ag/ml was inoculated with a stab from a glycerol stock. 
This was placed in the shaking incubator overnight at 37°C. Plasmid DNA 
was then isolated by using the Promega™ Wizard Plus SV miniprep 
purification kit as per the manufacturer’s instructions.
2.3.3 Preparation of Competent BL21 E.coli cells
An overnight culture of BL21 E.coli (protease-deficient strain) was 
grown in 3ml of LB broth containing 50pg/ml ampicillin. This culture was 
used to inoculate 250ml of LB broth which was grown at 37°C in a shaking 
incubator at 2 0 0  r.p.m until the ODeoo was 0.35-0.375. The bacteria were 
transferred to two pre-chilled centrifuge tubes and left for 1 hour on ice. The 
cells were sedimented by centrifugation for 20 minutes at 3500 g, and 
resuspended in 62.5ml of ice-cold 15% (v/v) glycerol with 0.1M calcium 
chloride. 250p.l of bacteria were aliquoted into sterile microfuge tubes in a 
dry/methanol bath to induce rapid freezing, and stored at -80°C.
2.3.4 Transformation of Competent BL21 E.cofi cells
Approximately 30-50ng of plasmid DNA was added to a pre-chilled 
microfuge tube on ice. An aliquot of competent bacteria was defrosted on
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ice, and SOjul added to each tube of plasmid DNA. This was incubated for 30 
minutes. The tubes were placed at 42“C for 2 minutes then placed back on 
ice and 0.5ml of LB broth was added. The tubes were then incubated at 37°C 
for 30 minutes to allow recovery. 0.1ml of the transformation mix was plated 
out onto agar plates containing 50pg/ml ampicillin and incubated overnight at 
37°C.
2.3.5 GST Fusion Protein Preparation
10ml of LBAmp broth (LB broth supplemented with ampicillin at a 
concentration of 50j,ig/ml) was inoculated from a glycerol stock of BL21 E.coli 
transformed with pGEX/PAKCRlB, which was then grown overnight, shaking 
at 37°C. This starter culture was then used to inoculate 400ml LBAmp, which 
was grown shaking, with aeration at 200 r.p.m for 3 hours (or until the 
ODeoo^O.S) at 37°C. The cells were induced by addition of IPTG to at a final 
concentration of lOmM, then grown shaking at 200 rpm for 3 hours at 37'^C.
The bacteria were harvested by centrifugation at 6700 g for 15 
minutes, the supernatant was discarded, the cells resuspended in 19.5ml 
PBS and transferred to a fresh tube. 0.5ml of 20% (v/v) Triton X-100 was 
added to the resuspended cells to give a final concentration of 0.5% (v/v) and 
the tube was inverted 6  times to mix. The sample was probe sonicated for 1 
minute on ice to ensure cell lysis and then centrifuged at 27000 g for 30 
minutes to pellet any insoluble material. The resulting cleared lysate was 
then added to 0.6ml of 50% (v/v) glutathione-Sepharose bead suspension 
and placed on a rotating wheel at 4°C overnight to allow the fusion protein to 
bind. The following day the beads were washed three times with 10ml of 
PBS. After the final wash the beads were resuspended in 50% (v/v) glycerol 
in PBS supplemented with protease inhibitors (0.1 mM PMSF, 10pg/pl 
soybean trypsin inhibitor and lOpg/fxl benzamidine) and stored at -20°C.
GST fusion protein concentration was determined by SDS PAGE 
using a 1 0 % (w/v) polyacrylamide resolving gel (as described in section 
2.4.3). The GST fusion protein was eluted from the glutathione-Sepharose 
beads with electrophoresis sample buffer (50mM TRIS (pH 6 .8 ), 10% (v/v) 
glycerol, 12% (w/v) SDS, 0.0001% (w/v) bromophenol blue, 6 pM DTT) and
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run on the gel in parallel with known BSA standards ranging from 0.2-4 pg/pl 
in amount. The gel was stained with Coomassie Brilliant Blue R-250 (0.25% 
(w/v) Coomassie Brilliant Blue R-250, 45% (v/v) methanol, 10% (v/v) acetic 
acid) for 1 hour shaking. The gel was rinsed in de-stain (50% (v/v) methanol, 
5% (v/v) acetic acid) and left overnight in de-stain. The gel was dried down 
under vacuum and the concentration of fusion protein was determined using 
the software TotalLab 2003.02 to detect the optical density of the bands. 
These values were then used to construct a straight line to ascertain the 
amount of fusion protein purified.
2.4 Laboratory Techniques
2.4.1 BOA Assay to Determine Protein Concentration
10 pt aliquots of BSA standards of known concentration ranging from 
0-2mg/ml and lOpI of unknown cell lysates were added in duplicate to a 96- 
well plate. 0.2ml of BCA solution (1% (w/v) 4,4 dicarboxy-2,2 biquinolin 
disodium salt, 2 % (w/v) sodium carbonate, 0.16% (w/v) sodium potassium 
tartrate, 0.4% (w/v) sodium hydroxide, 0.95% (w/v) sodium bicarbonate pH
11.25, 0.08% (w/v) copper (II) sulphate) was added to each well and left to 
incubate for 10 minutes at 37°C. Reduction of Cu^^ to Cu^ in a protein- 
specific manner allows the BCA to bind the Cu^ ion forming an intense purple 
colour, which is then measured at A492 using a plate reader. The absorbance 
values of the standards were used to construct a straight line from which the 
unknown protein concentrations were determined.
2.4.2 Bradford’s Assay to Determine Protein Concentration
lOpI aliquots of BSA standards of known concentration, ranging from 
0-2 mg/m I were added in duplicate to a 96-well plate. 2pl of unknown cell 
lysates and 8 pl of cell lysis buffer were also added in duplicate to the same 
96-well plate. The Bradford's reagent was diluted 1:5 and 50pl added to 
each well. The plate was left to incubate for 5 minutes at room temperature 
and then read on a plate reader at Aeso- The absorbance values of the 
standards were used to construct a straight line from which the unknown 
protein concentrations were determined.
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2.4.3 SDS-PAGE and immunoblotting
Samples to be prepared for SDS-PAGE were normalised for protein 
concentration using the BCA assay described in section 2.4,1. Each sample, 
equalised for protein concentration and volume was prepared in 
electrophoresis sample buffer (50mM TRIS (pH 6 .8 ), 10% (v/v) glycerol, 12% 
(w/v) SDS, 0.0001% (w/v) bromophenol blue, 6 pM DTT) and subjected to 
discontinuous SDS-PAGE alongside Rainbow Markers also prepared in 
electrophoresis buffer using a 1 0 % or 1 2 % polyacrylamide resolving gel 
(10%/12% (w/v) acrylamide, 0.3% (w/v) bisacrylamide, 0.4M TRIS (pH 8 .8 ), 
0.1% (w/v) SDS, 3% (v/v) glycerol, 0.01% (w/v) ammonium persulphate and 
0.001 %(v/v) TEMED) and a stacking gel (3% (v/v) acrylamide, 0.1% (v/v) 
bisacrylamide, 0.1 M TRIS (pH 6 .8 ), 0.1% (w/v) SDS, 0.01% (w/v) ammonium 
persulphate and 0.001% (v/v) TEMED).
Electrophoresis was performed using Biorad Mini-Protean I I/Ill gel 
electrophoresis systems with running buffer (24.7mM TRIS, 0.19M glycine 
and 0.1% (w/v) SDS) at 150 V (constant voltage) until the bromophenol blue 
dye front was at the bottom of the gel. The proteins were transferred 
electrophoretically to a nitrocellulose membrane at 400mA for 45 minutes in 
transfer buffer (24.7mM TRIS, 0.19M glycine and 20% (v/v) methanol). The 
membranes were rinsed briefly with PBS and non-specific protein binding 
sites were blocked for 1 hour at room temperature with Blotto [5% (w/v) 
skimmed milk containing either 0.1% (v/v) Triton X-100 or 0.1% (v/v) Tween- 
20 in PBS or TRIS-buffered saline (TBS)]. After blocking, the membranes 
were washed briefly in PBS or TBS. The primary antibody was diluted in 
Blotto or BSA (50mg/ml BSA in TBS) for phospho-specific antibodies. The 
membranes were incubated on a rotating platform overnight at 4°C, or at 
room temperature for 1 hour.
Following primary antibody incubation, the membranes were washed 
three times with Blotto or TBS supplemented with 0.1% (v/v) Tween-20 for 
phospho-specific antibodies. The membranes were incubated with a 1:1000 
dilution of the appropriate secondary antibody conjugated to HRP on a 
rotating platform for 1 hour at room temperature. Following secondary 
antibody incubation, the membranes were washed three times with Blotto 
and a further two times with PBS. Blots probed with a phospho-specific
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antibody were washed five times with TBS supplemented with 0.1% (v/v) 
Tween-20.
Membranes were exposed to enhanced chemiluminescence (ECL) 
reagents where HRP-specific oxidative degeneration of luminol causes the 
emission of light, which is detected by X-ray film to visualise immunoreactive 
proteins. The optical density of the bands were measured using the software 
TotalLab 2003.02 (Phoretix, UK).
2.4.4 Preparation of Stock 31P
0.66ml of methanol was used to resuspend Img of S IP  giving a final 
concentration of 4mM. The vial was closed tightly, sealed with Nescofilm and 
transferred to an 80°C oven. The vial was vortexed every 10 minutes until 
the S1P had dissolved, it was then pipetted in 25 pi aliquots into glass vials. 
The methanol was evaporated off using a stream of nitrogen gas. The tubes 
were then capped and stored at -80°G.
S IP  was reconstituted for use in serum-free DMEM supplemented 
with 0.5mg/ml fatty acid-free BSA. 0.25ml of vehicle was added to each vial 
and incubated at 37°C with repeated vortexing for 30 minutes. This gave a 
working S1P stock solution of 400pM.
2.4.5 Preparation of Stock FTY720P
1mg of FTY720P (compound 433) was dissolved in 50pl of 40% (w/v) 
hydroxypropyl-p-cyclodextrin, 5.16pl of 0.5M NagCOsand 944.84pl of distilled 
water in an ultrasonic water bath at 60°C for 30 minutes, giving a final 
concentration of 2.6mM. The solution was pipetted in 10pl aliquots into glass 
vials, capped and stored at -80°C. To reconstitute the FTY720P for use, 
2.6ml of serum-free DMEM supplemented with 0.5mg/ml fatty acid free BSA 
was added to each vial. This gave a working stock solution of lOpM.
2.4.6 Cell Surface Labelling of S1Pi with Biotin-LC-hydrazide
Confluent 75cm^ flasks of CCL39mycS1Pi cells were passaged at 1:8 
and seeded into 6 -well dishes and cultured overnight in DMEM. The next 
day the confluent cells were serum-starved for 16-20 hours in 3 ml of serum-
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free DMEM. The cells were treated with drugs as described in the Figure 
legend and receptor internalisation was initiated by addition of 4pM 81P for 2 
hours. The experiment was stopped by placing the cells on ice and all the 
following steps were carried out on ice unless otherwise stated.
Cell monolayers were washed three times with 2ml of ice cold PBS- 
CM (PBS supplemented with 1mM MgClg and 0.1 mM CaClg). Residual PBS- 
CM was removed and 1ml of 10mM sodium periodate in PBS-CM was added 
to each well to facilitate the oxidation of hydroxyl groups to aldehydes. The 
wells were covered and left to incubate for 30 minutes. After removal of 
sodium periodate, the monolayers were washed once with 2ml PBS-CM and 
then twice with 2ml of 0.1 M sodium acetate-CM (0.1M sodium acetate, pH 
5.5, supplemented with ImM MgCL and 0.1 mM CaCy. 0.1 mM of biotin-LC- 
hydrazide in sodium acetate-CM was added to each well, which were then 
covered and left to incubate for 30 minutes. The biotin was removed and the 
monolayers were washed with 2ml of PBS three times. After removal of 
residual PBS the cells were harvested in 0.25ml of RIPA buffer (50mM 
HEPES, pH 7.5, 150mM NaCI, 1% (v/v) Triton X-100, 0.5% (w/v) sodium 
deoxycholate, 0.1% (w/v) SDS with lOmM NaF, 5mM EDTA, lOmM Na2P0 4 , 
0.1 mM PMSF, 10pg/ml soybean trypsin inhibitor and lOpg/ml benzamidine) 
and each well was rinsed with a further 0.25ml of RIPA buffer, which was 
transferred to the appropriate tube. The samples were then solubilised on a 
rotating wheel at 4°C for 1 hour. Any insoluble material was pelleted by 
centrifugation at 20000 g for 15 minutes and 0.4ml of the supernatants were 
transferred to fresh microfuge tubes.
The concentrations of protein for each sample was determined by 
performing a BCA assay (as described in section 2.4.1). 0.4ml of sample 
normalised for protein concentration was added to a chilled microfuge tube 
containing 20pl of a 1:1 suspension of protein A-Sepharose beads, 0.2% 
(w/v) IgG-free BSA, 2^\ of rabbit anti-mouse bridging antibody and 5pl of 
9E10 ascites fluid. These were incubated on a rotating wheel at 4°C 
overnight. The immune complexes were isolated by brief centrifugation, 
washed with 1ml of RIPA buffer three times, then eluted from the beads by 
addition of 50|al electrophoresis sample buffer and incubation at 37°C for 1
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hour with brief vortexing every 15 minutes. Following elution, the samples 
were pelleted and the eluates removed with a Hamilton syringe. 25jliI of each 
sample was fractionated by SDS-PAGE, transferred to nitrocellulose and 
blocked with Blotto supplemented with 0.1% (v/v) Triton X-100 (as described 
in section 2.4,3).
Labelled cell surface receptors were identified by incubation of the 
membrane with 1 pg/ml of HRP-conjugated streptavidin, at room temperature 
for one hour and visualisation on autoradiography film by ECL.
2.4.7 Whole Cell Phosphorylation Assay
Confluent 75cm^ flasks of CCL39mycS1Pi cells were passaged at 1:8 
and seeded into 6 -well dishes and cultured overnight in DMEM 
supplemented with G418 sulphate. The following day the cells were serum- 
starved for 16-20 hours in serum-free DMEM, then washed twice with 
phosphate-free DMEM and incubated with 0.75ml of the same media 
supplemented with SOpCi/well p^P]-orthophosphate for 90 minutes at 37°C.
The cells were treated with drugs as indicated in Figure legends and 
then exposed to S IP  at a concentration of 5pM for 5 minutes. The reaction 
was terminated on ice and the monolayers were washed twice with ice-cold 
PBS. All subsequent steps were carried out on ice unless indicated 
otherwise. The cells were harvested in 0.25ml of RIPA buffer and transferred 
to a microfuge tube. Each well was then washed with a further 0.25ml of 
RIPA buffer, which was transferred to the appropriate tube. The cells were 
solubilised by rotation on a wheel for 1 hour at 4°C and analysed for protein 
content using the BCA assay (as described in section 2.4.1). Equivalent 
amounts of soluble protein from each sample were made up to 0.4ml in RIPA 
buffer and added to microfuge tubes containing 100pl of 0.2% (w/v) IgG-free 
BSA, 2pl goat anti-mouse IgG bridging antibody and 5j.il of ascites fluid 
generated against the myc-tagged receptor (9E10). The samples were 
incubated for 1 hour on a rotating wheel at 4°C. The immune complexes 
were then isolated by brief centrifugation and washed three times with 1 ml of 
RIPA buffer. Following washing, the samples were eluted from the beads by 
addition of 30j.il of electrophoresis buffer and incubation at 37°C for 1 hour,
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with vortexing every 15 minutes. The eluates were then analysed by SDS- 
PAGE using a 10% (w/v) polyacrylamide gel (as described in section 2.4.3), 
dried down under vacuum and phospho-proteins were visualised by 
autoradiography for between 16 and 20 hours at -80°C.
2.4.8 GST Pull Down Assay to Detect Small G protein Activation
Confluent 75cm^ flasks of CCL39 cells or CCL39mycS1Pi cells were 
passaged 1 :8  and seeded into either 6 -well or 1 0 cm dishes on plain tissue 
culture plastic, or tissue culture plastic coated with fibronectin or vitronectin 
(5pg/ml). The cells were cultured overnight in complete DMEM or complete 
DMEM supplemented with G418, respectively. The following day the 
monolayers were washed and incubated in serum-free media for 4 hours.
S IP  was then added to monolayers at a concentration of 5pM over a 
time course as indicated in the Figure legend. The time course was 
terminated by placing the cells on ice. Each subsequent step was carried out 
on ice unless otherwise stated. The cells were washed twice with ice cold 
PBS and harvested in 0.25ml of lysis buffer (50 mM HEPES pH 7.5, 100 mM 
NaCI, 1% (v/v) Triton X-100, supplemented with lOmM MgCE, lOmM NaF, 
5mM EDTA, lOmM Na2P0 4 . O.ImM PMSF, lOpg/ml soybean trypsin inhibitor 
and lOpg/ml benzamidine). Each well was washed with a further 0.25ml of 
lysis buffer, transferred to the appropriate tube and vortexed briefly. The 
insoluble material was then pelleted by centrifugation of the samples at 
20000 g for 15 minutes. 0.4ml of the cleared lysate was added to microfuge 
tubes containing 15|u.l of GST-PAKCRIB glutathione sepharose beads 
(concentration ranging between 70-90j.ig/pl) and lOOj l^ of 0.2% (w/v) IgG-free 
BSA. The remaining lysate was kept for a BCA assay (as described in 
section 2.4.1) and analysis by immunoblotting (as described in section 2.4.3).
The samples were placed on a rotating wheel at 4°C for 1 hour. The 
GST complexes were isolated by brief centrifugation and the supernatant 
discarded. The beads were then washed three times with 1ml of lysis buffer. 
GTP-bound small G proteins were eluted from the beads by addition of 30pl 
of electrophoresis buffer and incubation at 65°C for 20 minutes, with brief 
vortexing every 5 minutes. A BCA assay was used to calculate the volume to
96
be added to each lane to ensure equal concentration of input protein. The 
eluate and lysates were analysed by SDS PAGE using 12% (w/v) 
polyacrylamide resolving gels, transferred to nitrocellulose membranes and 
blocked with Blotto supplemented with 0.1% (v/v) Tween-20 (as described in 
section 2.4.1 and 2.4.3). GTP-bound small G proteins were detected by 
immunoblotting with the appropriate primary antibody as described in the 
Figure legend [368].
2.4.9 Assay of Caspase-3 Activity
Confluent 75cm^ flasks of CCL39 cells and CCL39mycS1Pi cells were 
subjected to serum deprivation for 16 hours and control flasks were cultured 
in complete media concurrently. The media from each flask was collected 
and transferred into appropriately labelled tube. The monolayers were 
washed with 5ml of PBS and this was transferred into respective tubes. 2ml 
of trypsin was added to each flask and left to incubate at room temperature 
till the cells had detached. 5ml of either complete DMEM or serum-free 
media was added respective flasks to neutralise the trypsin and wash any 
remaining cells from the flasks and this was transferred to respective tubes.
The tubes were centrifuged for 10 minutes at 4000 g to pellet the cells 
and the supernatants were discarded. The pellets were resuspended in 250pl 
of 1X Cell Lysis Buffer and transferred to fresh tubes. The tubes were placed 
on ice for 10 minutes and centrifuged for 5 minutes at 10000 g. The 
supernatants were transferred to fresh tubes, put on ice and the protein 
concentrations were determined by a Bradford assay (as described in section 
2.4.2) to ensure equal concentrations of protein were used in the activity 
assay. The assay mixtures were prepared in a 96-well plate (as shown in 
Table 2.1).
The caspase-3 inhibitor (Ac-DEVD-CHO) was incubated with the 
appropriate samples for 1 0  minutes at room temperature at a final 
concentration of 0.1 jaM prior to addition of substrate (Ac-DEVD-pNA). After 
substrate addition the 96-well plate was covered in aluminium foil and 
incubated at 37°C for 2 hours. A standard curve was prepared ranging from 
lOpM to ImM with the pNA standard provided with the kit. The plate was
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read at A405 on a plate reader. The background readings from the buffers 
were subtracted from the sample readings. Fold increase in caspase-3 
activity was determined by comparison of the optical density of the control 
cells with the cells subjected to serum deprivation.
Table 2.1 Caspase-3 Activity Reaction Mixtures
Assay Mixture
5X
Sample Assay
Buffer
Buffer 2 0 pl
Blank
Substrate 2 0 pl
Blank
Test 2 0 pl
sample
Test 2 0 pl
sample +
Inhibitor
 Caspase-3 Inhibitor clHgO 
Sample
80pl 
70pi
50ji! - 20pl
SOjLil 1 pi 19pl
Substrate Total
Volume
l O O p I
l O p I  l O O p I
l O p l  l O O p I
10p l  l O O p I
2.4.10 Detection of S IP 1 by Immunofluorescence
CCL39 cells stably transfected with mycSIPi from 1:10 split were 
seeded out onto sterile glass coverslips in a 6 -well dish and left to grow 
overnight. The next day the media was discarded and each monolayer 
washed three times in 1ml of PBS. To each well 1.5ml 4% (w/v) 
paraformaldehyde in a 5% (w/v) sucrose/PBS solution was added to fix the 
cells. This was allowed to incubate for 10 minutes at room temperature. The 
paraformaldehyde was discarded and the cells washed three times In 1 ml of 
PBS. 1.5ml of blocking solution (5% (w/v) skimmed milk containing 0 .1 % 
(v/v) Triton X-100) was added to each well and left to incubate for ten 
minutes at room temperature. The blocking solution was discarded and 
coverslips were then washed in 1ml of PBS. 0.2ml of primary antibody
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(5pg/ml) diluted in blocking buffer was dropped onto a strip of nescofilm and 
each coverslip was then placed inverted onto the drop of liquid. This was 
allowed to incubate for one hour at room temperature. The coverslips were 
returned to the 6 -well dish and washed three times in 1ml of PBS. 0.2ml of 
the secondary antibody (Alexa 594- or 488- conjugated) diluted in blocking 
buffer was dropped onto a strip of nescofilm and each coverslip was placed 
inverted onto the drop of liquid. The coverslips were covered and left to 
incubate for one hour at room temperature. The coverslips were returned to 
the 6 -well dishes washed three times in 1ml of PBS then allowed to dry. The 
coverslips were then mounted in 15pl of 40% (v/v) glycerol/PBS solution and 
stored at 4°C.
2.4.11 Detection of Stress Fibres with Alexa Fluor 594-conjugated 
Phalloidin
200pl of either CCL39 cells or CCL39 cells stably transfected with 
mycS1Pi from 1:10 split were seeded out onto sterile glass coverslips in a 6 - 
well dish and left to grow overnight. The next day the cells were serum- 
starved for 4 hours before stimulation with S IP  (5plVI) over a time course as 
indicated in the Figure legend.
The following steps were carried out at room temperature. The media 
was discarded and the coverslips were washed twice with 1ml of PBS. To 
each coverslip 1 ml of fixation buffer was added (4% (w/v) formaldehyde in a 
5% (w/v) sucrose/PBS solution) and left to incubate at room temperature for 
15 minutes. The monolayers were washed a further two times with 1ml of 
PBS before addition of 1ml of 0.1% (v/v) Triton X-100 for 2 minutes to 
permeablise cells. The coverslips were washed twice with 1ml of PBS before 
blocking with a 5% (w/v) BSA/PBS solution at room temperature for 30 
minutes.
The cells were stained with phalloidin conjugated to Alexa Fluor 594 
diluted 1:20 in a 5% (w/v) BSA/PBS solution. The coverslips were left to 
incubate for 30 minutes, then washed twice in 1ml of PBS prior to mounting 
in 40% (v/v) glycerol/PBS solution. Images were captured using a Zeiss 
fluorescence microscope and manipulated with Axiovision software.
99
2.4.11 Statistical Analysis
All statistical analyses were carried out using a one way AN OVA with 
a Bonferroni comparisons post test as described in the GraphPad software 
Instat 3.
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Chapter 3
S1Pi and Small G protein Activation Status
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3.1 Introduction
S1P is a bioactive lipid derived from the ubiquitous component of 
eukaryotic membrane sphingomyelin. It mediates its effects through family of 
GPCRs called S IP 1.5. S IP 1 was the first S1P receptor to be identified and is 
linked to multiple signalling pathways via the heterotrimeric G protein Gj. 
S IP 1 mediates many growth-related cell processes including cytoskeletal 
dynamics which are important in cell migration and angiogenesis. S IP  has 
been demonstrated to induce angiogenesis via PKB-mediated 
phosphorylation of eNOS and subsequent NO production [226]. In addition 
to angiogenesis, S IP  has an essential role in embryonic development. 
S1Pi-null mice die in utero at E12.5-E l3.5 due to massive haemorrhaging 
and inability to recruit stabilising pericytes to newly formed blood vessels 
[230].
Like all GPCRs, S IP 1 is subject to regulation by phosphorylation and 
internalisation. S IP 1 is regulated in part by agonist-dependent GRK-2 
mediated phosphorylation but is also phosphorylated in an agonist- 
independent manner by PKC. Phosphorylation by either of these kinases is 
associated with the loss of receptor from the cell surface [367]. The most 
studied form of internalisation is clathrin-mediated, where receptors are 
clustered in clathrin rich areas which are pinched off from the plasma 
membrane to form vesicles. This is mediated by small G proteins like Rab 
and Arf [150], however, the small G proteins generally associated with 
regulation of cytoskeletal processes, the Rho GTPases have been 
demonstrated to contribute to the efficiency of internalisation. For example, 
expression of the dominant negative from of Rac and RhoA were shown to 
attenuate clathrin-mediated internalisation of the transferrin receptor [185].
The protein kinase PKB has also been demonstrated to phosphorylate 
the S IP 1 receptor on the residue Thr236 which is situated in its third 
intracellular loop [126]. S IP 1 activates the PI 3-kinase pathway which results 
in the translocation and association of PKB to the plasma membrane via its 
PH domain. PKB and phosphoinositides have been shown to accumulate at 
the leading edge of migrating fibroblast cells stimulated with PDGF [369]. It 
has also been demonstrated that transactivation of the S IP 1 receptor by PKB 
is required for SIP-mediated migration of endothelial cells [126].
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Most cells respond to surfaces coated in ECM proteins by adhering to 
them and spreading out. This process is mediated by integhns and involves 
changes in cytoskeletal dynamics which are controlled by small G proteins 
like Rho, Rac and Cdc42. S1Pi expression and signalling has also been 
demonstrated to activate Rac in CHO cells [216] which is concentrated at the 
leading edge of migrating cells. By regulation of microfilament dynamics Rac 
mediates the formation of membrane ruffles termed lamellipodia. Cdc42 
regulates the formation of filopodia which are long, thin, actin-dependent 
protrusions of the plasma membrane [2 0 1 ] and is believed to control cell 
direction [166],
Rho-like GTPase signal transduction is tightly regulated by several 
classes of protein. Briefly, GEFs which activate small G proteins by 
catalysing the exchange of GDP for GTP, GAPs which inactivate small G 
protein by stimulating intrinsic GTPase activity favouring the GDP-bound 
state and GDIs which sequester small G proteins which also favours 
inactivation. There is evidence that specific GEF activity may in part 
determine the downstream effects elicited. For example, S IP  treatment of 
endothelial cells results in the translocation of Rac and its GEF Tiam-1 to the 
plasma membrane [227]. In addition to this, expression of dominant negative 
Tiam -1  was also demonstrated to attenuate SIP-mediated R ad  activation 
[124]. Once activated, GTP-bound Rac and Cdc42 stimulate various 
downstream targets, of which the first to be identified was p65PAK [370]. 
p65PAK targets downstream effectors such as LIMK and cofilin which 
ultimately results in actin polymerisation [162].
As mentioned previously, integrin interaction with ECM proteins such 
as fibronectin and vitronectin is important in the regulation of small G 
proteins. avPi or pa integhns that clustered to focal contacts were shown to 
be required for SIP-mediated migration in endothelial cells. This action was 
also blocked by 03 toxin but unexpectedly cell spreading and migration 
required the presence of both S1Pi and S IP 3 receptors [215].
Although a mechanism for Rac activation by 81 Pi has been described 
by Lee et al it is not known if this is a universal mechanism in all cell types. 
Chinese hamster lung fibroblast (CCL39) cells stably transfected with S IP 1 
provide a tractable model system to investigate whether disruption of the
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cytoskeleton has any effect on receptor regulation and what effect S1P has 
on Rac and Cdc42 activation in this system.
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3.2 Results
S1Pi has been demonstrated to control the activation status of 
cytoskeletal regulatory proteins such as Rac and Cdc42 thereby having a 
role in migration and angiogenesis [126, 230]. The Chinese hamster lung 
fibroblast cell line (CCL39) stably expressing S1Pi (CCL39mycS1Pi) [367] 
was used as a model to determine whether disruption of cytoskeletal 
processes would have an effect on receptor regulation by phosphorylation 
and internalisation. Myc-tagged receptor expression was confirmed by 
immunofluorescence microscopy where the myc epitope and the S1Pi 
antibody were shown to localise (Figure 3.1). As there is no suitable 
radioligand available the number of receptors expressed on the cell surface 
was not assessed.
Whole cell phosphorylation assays were used to detect any change in 
the level of agonist-induced receptor phosphorylation in response to various 
inhibitors of cytoskeletal dynamics. An inhibitor of microtubule dynamics, 
colchicine had no effect on the level of receptor phosphorylation (Figure 3.2). 
Another inhibitor, cytochalasin B which prevents the polymerisation of 
microfilaments also had no effect on agonist-induced phosphorylation (Figure 
3.3). Furthermore, pertussis toxin which inactivates Gj had no effect on 
agonist-induced receptor phosphorylation (Figure 3.4). To examine whether 
receptor internalisation was affected by these same inhibitors cell surface 
receptors were labelled with biotin-LC-hydrazide. Again, none of these 
inhibitors had any significant effect on receptor internalisation (Figure 3.5). 
Thus, it appears that disruption of the cytoskeleton with inhibitors has no 
effect on receptor regulation by phosphorylation or internalisation.
The level of Rac expressed in CCL39mycS1Pi cells is significantly 
lower than in control CCL39 cells but removal of serum rescues partially this 
effect (Figure 3.6a and Figure 3.6b). To assess how this would affect the 
ability of S1Pi to activate Rac a pull down assay was employed using the 
fusion protein GST-PAKCRIB which detects GTP-bound Rac (Figure 3.9b) 
compared to total levels of Rac by western blot. In control CCL39 cells no 
S1P-induced Rac activation was detected over a time period of 15 minutes 
(Figure 3.7). As the GST fusion protein PAKCRIB also binds to GTP-bound 
Cdc42 the levels of active Cdc42 were also determined by western blot and
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like Rac, there was no detectable activation of Cdc42 in control CCL39 cells 
(Figure 3.8). To determine whether expression of S1Pi would result S1P- 
induced Rac and Cdc42 activation the same experiments were repeated in 
CCL39mycS1Pi cells. However in contrast to the expected result there was 
no significant increase in Rac activation above the basal levels of GTP-bound 
Rac detectable, which is not reflected in the total levels of Rac (Figure 3.9a). 
This effect was not restricted to Rac alone but was observed in Cdc42 
activation levels also (Figure 3.10).
As integrin engagement is a known inducer of small G protein 
activation [200] the level of GTP-bound Rac and Cdc42 was assessed in 
CCL39mycS1Pi cells that had been cultured on the ECM protein fibronectin. 
However, there was no significant increase in the level of GTP-bound Rac or 
Cdc42 in response to S IP  and integrin engagement (Figures 3.11 and 3.12). 
The same was observed in CCL39mycS1Pi cells cultured on vitronectin 
(Figures 3.13 and 3.14).
It is well documented that S1Pi induces Rac activation [126, 216], 
however, the S IP 2 receptor has a negative effect on the activation status of 
Rac. S IP 2 is reported to be expressed in this cell type [64] so to investigate 
whether endogenous S IP 2 was inhibiting SIP-mediated Rac activation, the 
selective S IP  receptor agonist FTY720P, which does not stimulate the S IP 2 
receptor [244] was utilised. FTY720P is a potent agonist of S IP 1 and 
activates ERK in a dose dependent manner in CGL39mycS1Pi cells 
(ECso=12.2pM) (Figure 3.15). FTY720P also activates ERK in a time- 
dependent manner in a comparable manner to S IP  in CCL39mycS1Pi. 
Stimulation by either S1P or FTY720P causes a significant increase in the 
level of phosphorylated ERK detected by 2 minutes and peaks at 5 minutes. 
This indicates that the recombinant receptor is functioning correctly. It also 
suggests that if there is an endogenous receptor negating the S IP 1 
receptor’s ability to activate ERK then the receptor responsible does not 
activate ERK (Figures 3.16 and 3.17). However, the selective agonist 
FTY720P does not stimulate Rac or Cdc42 activation in CCL39mycS1Pi 
cells (Figures 3.18 and 3.19). Thus, it appears that the ability of S IP  to 
activate Rac and Cdc42 in this system is not due to expression of 
endogenous S IP 2.
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Thus, to confirm the lack of Rac activation in response to S1P both 
control cells and CCL39mycS1Pi cells were stained with Alexa fluor 594- 
conjugated phailoidin which binds to actin microfilaments. In both control 
CCL39 and CCL39mycS1Pi cells by 30 minutes there were detectable stress 
fibres present in CCL39mycS1Pi. The formation of lameilipodia was also 
observed (Figure 3.20 and 3.21).
107
3.3 Discussion
S1Pi has been shown to regulate the activation status of small G 
proteins in a number of cell types and is thereby considered an important 
mediator of not only cell migration but angiogenesis also. Gaining insight into 
S1Pi signalling has therapeutic potential in a number of disease states 
including artherosclerosis and cancer.
The current explanation for transactivation of Rac by PKB is unlikely to 
be a universal mechanism since using CCL39mycS1Pi cells it was 
demonstrated that PKB does not phosphorylate S1Pi (data not shown) in this 
system. However, the inability to detect Rac or Cdc42 activation in 
GCL39mycS1Pi cells was an unexpected result as there are several reports 
implicating S1Pi as an activator of small G proteins in various cell types [126, 
216, 371]. The GST-fusion protein employed to detect small G protein 
activatlon-GST-PAKCRIB contains the recognition site for GTP-bound 
Rac/Cdc42 of their downstream target p65PAK. The constitutively active 
form of Rac, L61 was isolated using GST-PAKCRIB confirming that the 
fusion protein was functioning correctly (Figure 3,9b). The non-hydrolysable 
analogue GTPyS was also detected in the pull down assays also indicating 
that the assay was working. Although it may have been beneficial to use an 
assay detecting GTPase activity as GTP-bound small G proteins have 
intrinsic GTPase activity in addition to this [371].
CCL39mycS1Pi showed a significant decrease in the level of Rac 
expression compared to parental cells Figure (3.5a). Serum starvation of 
CCL39mycS1Pi cells partially rescued this effect (Figure 3.5b). Constitutive 
activity of S1Pi in this model system was observed with respect to protection 
from serum withdrawal-induced apoptosis (see Chapter 4) so it is therefore 
probable that receptor over-expression caused the down-regulation of Rac 
observed in CCL39mycS1Pi. However the western blots of cell lysates from 
pull down assays show consistent levels of total Rac (and Cdc42) which were 
easily detectable. Although not significant, the basal levels of active Rac 
present in untreated CCL39mycS1Pi cells were elevated compared to S IP 
treated cells which is also indicative of constitutive activity (Figures 3.9a and 
3.11). The recombinant receptor appears to be functioning correctly as
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agonist stimulation results in ERK activation in a time dependent manner 
(Figure 3.16).
S IP 2 has been documented to inhibit Rac activation and migration 
[216] but S IP 2 RNA was not detected in CCL39 cells by northern blot 
analysis (data not shown). In addition to this the use of the selective inhibitor 
FTY720P which is a potent activator of all S IP  receptors bar S IP 2 did not 
result in detectable Rac or Cdc42 activation in response to S IP  in 
CCL39mycS1Pi cells (Figure 3.18 and 3.19). This agonist was functioning 
correctly as it stimulated ERK in a time and dose-dependent manner (Figures 
3.15 and 3.17). Thus, it can be deducted that the lack of SIP-induced Rac 
and Cdc42 activation is not due to endogenous S IP 2 expression.
Since S IP  stimulation does not induce Rac or Cdc42 activation in this 
cell type it might have been beneficial to try cell line where the receptor is 
expressed endogenously. The rate limiting step in activation of small G 
protein is the exchange of GDP for GTP [150] and if the appropriate GEF 
was not expressed or available in the locality this may effect activation levels. 
For example, the Rac-GEF Tiam-1 translocates to the plasma membrane 
where Rac is also concentrated to induce Rac activation and subsequent 
migration [164]. In both control CCL39 cell and CCL39mycS1Pi cells stress 
fibres were detected (Figure 3.20 and 3.21). At 30 minutes lamellipodial 
structures were observed in CCL39mycS1Pi cells treated with S IP  (Figure 
3.21). The presence of lameilipodia suggests there may be low levels of 
localised Rac activation but it is undetectable biochemically. Although well 
documented in other cell types it appears that SIP-induced Rac and Cdc42 
activation does not occur in this model system.
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Figure 3.1 Confocal Image of CCL39 Cells Stably Expressing the Myc 
Epitope Tagged Receptor 31 Pi
CCL39 ceils stably expressing the recombinant mycS1Pi were 
incubated with antibodies recognising the myc epitope tag (9E10 1:200) and 
the SI Pi receptor (5pg/ml). The secondary antibodies used were Alexa 488- 
and 594-conjugated. The image on the far right shows the merge and co­
localisation of the myc tag and the SI Pi receptor The image was captured 
while using a 40 X objective lens.
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Figure 3.2 The Effect of the Cytoskeletal Inhibitor Colchicine on 
Levels of S1Pi Receptor Phosphorylation.
The autoradiographs show the level of mycS1Pi receptor 
phosphorylation. CCL39 cells that stably express mycS1Pi were labelled 
with p P ] orthophosphate for 90 minutes prior to a 30 minute treatment with 
an inhibitor of microtubule polymerisation, colchicine in concentrations 
ranging from 0,01 pM to lOpM. The cells were then stimulated with S IP  at a 
concentration of SpM for 5 minutes. Labelled mycSIPi was detected by 
immunoprécipitation and visualised by autoradiography. The level of total 
receptor was detected by western blotting. This Figure is representative of 3 
experiments and the graph shows the percentage maximal stimulation.
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Figure 3.3 The Effect of the Cytoskeletal Inhibitor cytochalasin B on 
Levels S1Pi Receptor Phosphorylation.
The autoradiographs show the levels of mycS1Pi receptor 
phosphorylation. CCL39 cells stably expressing mycSIPi were labelled with 
p P ] orthophosphate for 90 minutes prior to a 30 minute treatment with 
cytochalasin B, an inhibitor of actin polymerisation in concentrations ranging 
from 0.01 pM to lOpM. The cells were then stimulated with S1P at a 
concentration of 5pM for 5 minutes mycSIPi was detected by 
immunoprécipitation. Labelled mycSIPi was detected by
immunoprécipitation and visualised by autoradiography. The level of total 
receptor was detected by western blotting. This Figure is representative of 3 
experiments and the graph shows the percentage maximal stimulation.
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Figure 3.4 The Effect of Pertussis Toxin on Levels S1Pi Receptor 
Phosphorylation.
The autoradiographs show levels of mycSIPi receptor 
phosphorylation. CCL39 cells stably expressing mycSIPi were treated with 
pertussis toxin (PTX) for 18 hours in concentrations ranging from Ing/ml to 
lOOng/ml. The cells were labelled with [^^P] orthophosphate for 90 minutes 
prior to stimulation with S IP  at a concentration of 5pM for 5 minutes. 
MycSIPi was detected by immunoprécipitation. Labelled mycSIPi was 
detected by immunoprécipitation and visualised by autoradiography. The 
level of total receptor was detected by western blotting. This Figure is 
representative of 3 experiments and the graph shows the percentage 
maximal stimulation.
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Figure 3.5 The Effect of Cytoskeletal Inhibitors on Agonist-induced 
S1Pi Receptor Internalisation.
This Figure shows the detection of cell surface labelling of mycS1Pi 
with biotin-LC-hydrazide. CCL39 cells stably expressing mycS1Pi were 
treated with the cytoskeletal inhibitors colchicine and cytochalasin B at a 
concentration of 10|j,M and pertussis toxin (PTX) at a concentration of 
100ng/ml. The cells were stimulated with S1P at a concentration of SpM for 
90 minutes. The receptors were immunoprecipitated and cell surface 
receptors detected by HRP-streptavidin. The level of total receptor was 
detected by western blotting. This Figure is representative of 3 experiments 
and the graph shows cell surface receptor detected.
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Figure 3.6 Detection of Rac in CCL39 Cells Over-expressing mycS1Pi
(a) Detection of Rac in CCL39 over-expressing mycSIPi compared to 
parental CCL39 cells, which have been cultured in complete media by 
western blot,
(b) Detection of Rac in CCL39 cells over-expressing m ycSIPi compared 
to parental CCL39 cells which have been serum-starved for 4 hours by 
western blot.
The cells were cultured, lysates prepared and the concentration of protein 
equalised, p values are from a one way AN OVA with a Bonferroni 
comparisons test, bars marked with *** have a p<0 .0 0 1  and those marked 
with * have a p<0.05. Levels of mycS1Pi and GAPDH were also 
determined by western blot.
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Figure 3.7 The Effect of S1P Stimulation on Rac Activation Status in 
Parental CCL39 Cells.
Detection of GTP-bound Rac in parental CCL39 cells that have been 
stimulated with S1P (5pM) by western blot. Parental CCL39 cells were 
serum-starved for 4 hours prior to stimulation with S1P for 0.5, 1, 5 and 15 
minutes. GTP-bound Rac was isolated using the GST fusion protein 
PAKCRIB. Total Rac was also determined by western blot and this Figure is 
representative of three experiments.
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Figure 3.8 The Effect of S1P Stimulation on Cdc42 Activation Status 
in Parental CCL39 Cells.
Detection of GTP-bound Cdc42 in parental CCL39 cells that have 
been stimulated with S1P by western blot. CCL39 cells were serum-starved 
for 4 hours prior to stimulation with S1P at a concentration of 5pM for 0.5, 1, 
5 and 15 minutes. GTP-bound Cdc42 was isolated using the GST fusion 
protein PAKCRIB. The total level of Cdc42 was also determined by western 
blot. This Figure is representative of two experiments.
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Figure 3.9 Rac Activation Status in SiP-stimulated CCL39mycS1Pi
Cells
(a) CCL39mycS1Pi cells were serum-starved for 4 hours prior to 
stimulation with 81P at a concentration of SpM for 0.5, 1, 5 and 15 
minutes. GTP-bound Rac was isolated using the GST fusion 
protein PAKCRIB and detected by western blot. The level of total 
Rac was also detected by western blot. The Figure is a 
representative of three experiments,
(b) The above experiment was repeated but with the constitutively 
active L61Rac control included. L61Rac was detected by western 
blot as above.
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Figure 3.10 Cdc42 Activation Status in SIP-stimulated CCL39mycS1Pi
Cells
CCL39mycS1Pi ceils were serum-starved for 4 hours prior to 
stimulation with S IP  at a concentration of 5p,M for 0.5, 1, 5 and 15 minutes. 
GTP-bound Cdc42 was isolated using the GST fusion protein PAKCRIB and 
detected by western blot. The level of total Gdc42 was also determined by 
western blot. This Figure is a representative of three experiments.
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Figure 3.11 The Effect of S IP  Stimulation on Rac Activation Status in 
CCL39mycS1Pi Cells Cultured on FIbronectin
Levels of GTP-bound Rac in 81P stimulated CCL39mycS1Pi cells 
cultured on fibronectin. CCL39mycS1Pi cells were plated out on tissue 
culture dishes coated with fibronectin at a concentration of 5jig/ml. The next 
day, the cells were serum-starved for 4 hours prior to stimulation with S1P at 
a concentration of 5).iM for 0.5, 1, 5 and 15 minutes. GTP-bound Rac was 
isolated using the GST fusion protein PAKCRIB and detected by western 
blot. The level of total Rac present was also detected by western blot and 
this Figure is a representative of three experiments, p values are from a one 
way ANOVA with a Bonferroni comparisons test, bars marked with * have a 
p<0.05.
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Figure 3.12 The Effect of S IP  Stimulation on Cdc42 Activation Status 
in CCL39mycS1Pi Cells Cultured on Fibronectin
The levels of GTP-bound Cdc42 in 81P stimulated CCL39mycS1Pi 
cells cultured on fibronectin. CGL39mycS1Pi cells were plated out on tissue 
culture dishes coated with fibronectin at a concentration of Spg/ml. The next 
day, the cells were serum-starved for 4 hours prior to stimulation with S IP  at 
a concentration of 5pM for 0.5, 1, 5 and 15 minutes. GTP-bound Cdc42 was 
isolated using the GST fusion protein PAKCRIB and detected by western 
blot. The levels of total Cdc42 present were also determined by western blot 
and this Figure is a representative of two experiments.
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Figure 3.13 The Effect of S1P Stimulation on Rac Activation Status in 
CCL39mycS1Pi Cells Cultured on Vitronectin
The levels of GTP-bound Rac in 81P stimulated CCL39myc81Pi cells 
cultured on vitronectin. CCL39myc81Pi cells were plated out on tissue 
culture dishes coated with vitronectin at a concentration of 5pg/ml. The next 
day, the cells were serum-starved for 4 hours prior to stimulation with 81P at 
a concentration of 6 pM for 0.5, 1, 5 and 15 minutes. GTP-bound Rac was 
isolated using the G8 T fusion protein PAKCRIB and detected by western 
blot. The level of total Rac was also determined by western blot and this 
Figure is a representative of three experiments.
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Figure 3.14 The Effect of S1P Stimulation on Cdc42 Activation Status 
in CCL39mycS1Pi Cells Cultured on Vitronectin
The levels of GTP-bound Cdc42 in S1P stimulated GGL39mycS1Pi 
cells cultured on vitronectin. GGL39mycS1Pi cells were plated out on tissue 
culture dishes coated with vitronectin at a concentration of 5pg/ml. The next 
day, the cells were serum-starved for 4 hours prior to stimulation with S1P at 
a concentration of 5uM for 0.5, 1, 5 and 15 minutes. GTP-bound Gdc42 was 
isolated using the GST fusion protein PAKGRIB and detected by western 
blot. The level of total Gdc42 present was also determined by western blot 
and this Figure is a representative of two experiments.
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Figure 3.15 Detection of Dose-Dependent ERK Activation in 
CCL39mycS1Pi Cells Stimulated with FTY720P
Both parental CCL39 cells and CCL39mycS1Pi cells were deprived of 
serum for 4 hours prior to stimulation with FTY720P at concentrations 
ranging from 10‘^^  to 10'^, for 15 minutes. The level of phospho-ERK and 
total ERK was determined by western blot, th is  Figure is a representative of 
three experiments.
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Figure 3.16 Detection of ERK Activation in CCL39mycS1Pi Cells 
Stimulated with 31P
The time dependent effect of 81P stimulation on ERK activation in 
both parental CCL39 cells and CCL39mycS1Pi cells. These cells were 
serum-starved for 4 hours prior to stimulation with S IP  at a concentration of 
5pM for 2, 5, 15 and 30 minutes and FTY720P for 15 minutes at a 
concentration of 0.1 pM. Phospho-ERK (P-ERK) and total ERK were 
detected by western blot. This Figure is a representative of three 
experiments and bars marked with *** have a p value of <0 .0 0 1 .
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Figure 3.17 Detection of ERK Activation in CCL39mycS1Pi Cells 
Stimulated with FTY720P
The time-dependent effect of FTY720P on ERK activation in both 
control CCL39 cells and CCL39mycS1Pi cells. The cells were serum-starved 
for 4 hours prior to stimulation with FTY720P at a concentration of 0.1 )aM for 
2 , 5 , 1 5  and 30 minutes and S IP  for 15 minutes at a concentration of 5pM. 
Phospho-ERK (P-ERK) and total ERK were detected by western blot. This 
Figure is a representative of three experiments and bars marked with *** 
have a p value of <0 .0 0 1 .
142
FTY720P (0.1 pM) 
SIP (5pM)
Time (minutes)
CCL39 CCL39mycS1Pi
“  +  +  + +  -  “  +  +  +  +  “
0 2 5 15 30 15 0 2 5 15 30 15
P-ERK
Total ERK
lOOi
rn  Control
■  FTY720P(0.1pW)
■  S1P(5pM)
0 2 5 15 30 15 0 2 5 15 30 15
CCL39 CCL39fnycS1Pi
Time stimulated with agonist (minutes)
143
Figure 3.18 The Effect of FTY720P Stimulation on the Rac Activation 
Status in CCL39mycS1Pi Cells
The level of GTP-bound Rac in FTY720P stimulated CCL39mycS1Pi 
cells. CCL39mycS1Pi cells were serum-starved for 4 hours prior to 
stimulation with FTY720P at a concentration of 0.1 pM for 0.5, 1, 5 and 15 
minutes. GTP-bound Rac was isolated with the GST fusion protein PAKCRIB 
and detected by western blot. The level of total Rac was also detected by 
western blot and this Figure is a representative of three experiments.
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Figure 3.19 The Effect of FTY720P Stimulation on the Cdc42 Activation 
Status in CCL39mycS1Pi Cells
The level of GTP-bound Cdc42 in FTY720P stimulated 
CCL39mycS1Pi cells. CCL39mycS1Pi cells were serum-starved for 4 hours 
prior to stimulation with FTY720P at a concentration of 0.1|aM for 0.5, 1, 5 
and 15 minutes. GTP-bound Cdc42 was isolated with the GST fusion protein 
PAKCRIB and detected by western blot. The level of total Cdc42 was also 
detected by western blot and this Figure is a representative of three 
experiments.
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Figure 3.20 Detection of Stress Fibres in Control CCL39 Cells Treated 
with S1P
Control CCL39 cells treated with 81P (5jiM) over a time course of 2, 
5, 15 and 30 minutes. Stress fibres were detected by staining with Alexa 
fluor 594-conjugated phalloidin. Images were captured using a Zeiss 
microscope (40 x objective lense) and manipulated with Axiovision software.
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Figure 3.21 Detection of Stress fibres in CCL39mycS1Pi Cells Treated 
with S1P
CCL39mycS1Pi cells treated with S1P (5|aM) over a time course of 2, 
5, 15 and 30 minutes. Stress fibres were detected by staining with Alexa 
fluor 594-conjugated phalloidin. Images were captured using a Zeiss 
microscope (40 x objective lense) and manipulated with Axiovision software.
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Chapter 4 
Regulation of Apoptosis by S1P
152
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Regulation of Apoptosis by S1 Pi
4.1 Introduction
Apoptosis is a strictly regulated process of cell destruction that plays 
an essential role in both embryonic development and tissue homeostasis in 
the adult organism. It is characterised by nuclear and cytoplasmic 
condensation which results in the formation of apoptotic bodies that are 
recognised, ingested and degraded by neighbouring cells [256].
Programmed cell death can be instigated by the activation of death 
receptors such as the Fas receptor, but can also be initiated by extrinsic 
means like the removal of trophic factors [293, 299]. The removal of survival 
factors has been demonstrated to cause the increase in activity of pro- 
apoptotic BH3-only proteins, such as Bim in various cells types including 
fibroblasts [274] and haematopoietic cells [271]. In viable cells, Bim remains 
sequestered by the anti-apoptotic protein Mcl-1. However, another BH3-only 
protein [298], Noxa, regulates the proteosomal degradation of Mcl-1, which
1.allows the liberated Bim to promote cytochrome c release by activating pro- 
apoptotic Bcl-2 proteins [372]. Bim is subject to negative regulation via ERK- 
mediated phosphorylation which promotes its degradation [274, 275], 
whereas phosphorylation by JNK promotes the release of Bim from 
microtubules allowing the liberated Bim to promote the release of cytochrome 
c from the mitochondria [278]. Cytochrome c release triggers the initiation of 
the caspase cascade and the subsequent activation of caspase-3 [311].
Caspase-3 is termed an executioner caspase as its activation is deemed to 
be the point of no return for the cell [283]. Substrates for proteolysis by 
caspases include structural proteins homeostatic proteins and DNases which 
induce the apoptotic phenotype and also pro-caspases which serve to 
amplify the apoptotic signal [260].
S IP  and its derivative sphingosine have long been recognised as 
important mediators of programmed cell death. For example, activation of 
SphK and the concomitant production of S IP  protects cells from apoptosis by 
serum deprivation, in fact, SphKi activation has been associated with the 
down-regulation of Bim in HUVECs but it is unknown if this action is sufficient 
to promote survival [333]. S1P is secreted from various cell types, including 
fibroblasts and activated platelets and exerts its effects via the cell surface
153
receptors S IP 1-5 . Extracellular S1P is mainly bound to HDLs which act as 
carriers that promote the binding of S1P to S IP 3 resulting in the activation of 
eNOS and production of cryoprotective NO [345, 348]. The S IP 1 receptor is 
believed to localise to caveloae upon agonist binding and is also believed to 
promote the activation of eNOS [359]. Stimulation of S IP 1 also results in the 
PKB-mediated activation of eNOS [207, 361].
Bim is also believed to be involved with a specific form of cell death 
termed anoikis which is caused by the detachment of cells from their 
substratum [373]. An investigation of anoikis in an immortalised breast 
epithelial cells showed an elevation in expression of all three endogenous 
Bim isoforms which is reversed by the hyper-activation of EOF receptor 
mediated activation of the MAPK/ERK pathway [374]. In particular relevance 
to this thesis, the down-regulation of PKB by proteolytic degradation in 
CCL39 cells undergoing anoikis and that activation of PKB required adhesion 
to the substratum [197]. The transcription factor Fox03a has been 
implicated in the up-regulation of Bim expression induced by the cancer drug 
paclitaxel. The FoxO transcription factors are subject to regulation by PKB 
phosphorylation which not only impairs their ability to bind DNA but increases 
their affinity for 14-3-3 proteins [375-378].
S IP 1 receptor signalling is associated with many growth-related cell 
processes and is acknowledged to enhance survival. Flowever, the 
mechanism S IP 1 utilises to promote survival remains unclarified. The 
response of CCL39 cells to the removal of trophic factors is well documented 
[379, 380] so CCL39 stably expressing mycS1Pi cells were utilised as a 
tractable model system to investigate the mechanisms by which the S IP 1 
receptor may employ.
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4.2 Results
The cryoprotective role of S1Pi is documented in endothelial cells but 
it is unknown if (a) this is a general feature of S1Pi signalling irrespective of 
cell type, or (b) the mechanism is conserved between different types of cells. 
The regulation of Bim by phosphorylation by JNK and ERK has been 
characterised in CCL39 cells [274, 380]. To determine how CCL39 cells and 
CCL39 cells stably expressing the myc epitope-tagged S1Pi receptor 
(CCL39mycS1Pi) would respond to removal of trophic factors they were 
cultured in serum-free conditions over a period of 24 hours. In response to 
serum deprivation the majority of control CCL39 cells had rounded up and 
detached from the substratum by 24 hours (Figure 4.1). However, 
CCL39mycS1Pi cells were resistant to serum deprivation-induced anoikis 
and continued to proliferate even after subjection to serum-free conditions for 
24 hours (Figure 4.2). To assess whether the CCL39 cells were apoptotic, 
the level of cleaved, active caspase-3 was determined by western blotting. In 
response to serum deprivation, control CCL39 cells showed a significant 
increase in the levels of cleaved caspase-3 at 6  hours, which peaked at 12 
hours and was still detected at 24 hours. However, the level of cleaved 
caspase-3 in CCL39mycS1Pi cells did not rise significantly above the basal 
level at any point over the 24 hour time course (Figure 4.3). To ensure that 
detection of cleaved caspase-3 by western blot was an accurate marker for 
cells undergoing apoptosis a colorimetric assay of caspase-3 activity was 
employed. In serum-deprived control CCL39 cells, caspase-3 activity was 
elevated (3pmol/min) compared to those cultured in serum, in which no 
significant levels of caspase-3 activity could be detected. This increase in 
activity was blocked by the presence of the specific caspase-3 inhibitor 
AcDEVD-CHO. However, caspase-3 activity was decreased (0.23pmol/min) 
in CCL39mycS1Pi cells, compared to control CCL39 cells. In addition to 
this, caspase-3 activity was undetectable in the presence of serum or the 
inhibitor AcDEVD-CHO. This correlates with the serum withdrawal-induced 
caspase-3 cleavage detected by western blotting (Figure 4.4).
The apoptosis initiator protein, Bim, has been shown to be up- 
regulated in GGL39 cells in response to serum deprivation [274]. So to 
determine if the expression of 81 Pi has any effect on Bim induction, the level
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of Bim present in serum-deprived control CCL39 cells and CCL39mycS1Pi 
was also detected. The expression of Bim was promoted in response to 
serum deprivation and had increased significantly above the basal level by 3 
hours in control CCL39 cells, thereby preceding caspase-3 activation as 
expected. Bim levels did not rise significantly above the basal in 
CCL39mycS1Pi cells at any point over the 24 hour time course (Figure 4.5). 
Thus, serum deprivation of CCL39 cells induces an apoptotic phenotype 
which is confirmed by the concurrent increase in Bim expression and 
caspase-3 activation. However, the over-expression of S1Pi attenuates the 
rise in Bim expression and caspase-3 activation thereby promoting survival.
To determine whether agonist stimulation of S1Pi would enhance this 
effect, S1P and the selective agonist FTY720P were introduced to both 
control CCL39 cells and CCL39 mycS1Pi cells after 16 hours of serum 
starvation. FTY720P, which is a potent agonist of all S IP  receptors except 
S IP 2 , significantly decreased the level of cleaved caspase-3 in 
CCL39mycS1Pi cells (Figure 4.6). However, FTY720P stimulation of S IP 1 
had no significant effect on the expression levels of Bim (Figure 4.7). To 
assess whether intracellular levels of S1P may influence the observed effect 
of S IP 1 expression, the competitive SphK inhibitor dihydrosphingosine (DHS) 
was added to prevent endogenous S IP  production. This had no effect on 
either caspase-3 cleavage or Bim expression in control CCL39 cells or 
CCL39mycS1Pi cells (Figure 4.8 and 4.9). The constitutive protective effect 
of S IP 1 over-expression is not due to the autocrine production of SIP. 
Furthermore the S1Pi-mediated down-regulation of caspase-3 cleavage is 
not dependent on the down-regulation of Bim.
To determine which signalling pathways may be involved in the SI Pi- 
mediated inhibition of apoptosis a number of selective inhibitors of S1P- 
acitvated pathways were tested for their effects on Bim induction and 
caspase-3 cleavage. The MEK inhibitor U0126 had no effect on caspase-3 
cleavage suggesting that serum-withdrawal induced apoptosis in CCL39 cells 
in not mediated by ERK. Pertussis toxin caused a significant increase in 
caspase-3 cleavage in CCL39mycS1Pi cells confirming that the observed 
protection is Gj-linked. Although not significant, an increase in Bim 
expression was observed in U0126 treated cells which did not result in
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increased caspase-3 cleavage, consistant with the possibility that an 
increase in the level of Bim expression alone may not be sufficient to induce 
caspase-3 cleavage and apoptosis (Figure 4.10).
To determine the specific signalling pathways involved, selective 
inhibitors of other SI Pi-mediated pathways were used. Treatment with PI3 
kinase inhibitor LY294002 showed a significant increase in caspase-3 
cleavage and although the PKC inhibitor GF109203X also showed an 
increase in caspase-3 cleavage it was not significant. However, the addition 
of both inhibitors together shows a dramatic increase in the amount of 
cleaved caspase-3 detected, completely blocking its down-regulation by 
SI Pi (Figure 4.11). Furthermore, the level of Bim in the cell appears to be 
unaffected by the attenuation of S1Pi-mediated inhibition of caspase-3 
cleavage which suggests another level of regulation (Figure 4.12). To 
assess whether the S1Pi receptor was driving the synthesis of a pro-survival 
mediator, the chemical emetine was used to block protein synthesis. This 
treatment resulted in a 6 -fold increase in caspase-3 cleavage despite the 
presence of SI Pi. The expression of Bim appears to decrease over the time 
course, however, the rate of change between control CCL39 cells and 
CCL39mycS1Pi cells is not significantly different (Figure 4.13). This 
suggests that the 81 Pi receptor is driving the expression of a pro-survival 
mediator that protects the cell form serum withdrawal-induced apoptosis.
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4.3 Discussion
S1P is an important regulator in apoptosis, this chapter shows that the 
receptor S1Pi has a protective effect against serum-withdrawal induced 
apoptosis in CCL39 fibroblasts. Although the level of the S1Pi receptor 
expression in the stably transfected CCL39 cell is unknown, its presence 
seems to be sufficient to confer protection against apoptosis by serum 
deprivation. This effect is observed in the absence of agonist and whilst j-inhibiting endogenous S1P production by SphK (Figures 4.3 and 4.8). This 
implies that there may be sufficient numbers of receptors spontaneously 
adopting an active conformation, thereby driving receptor signalling. This 
could be determined by using the radioligand [^H]-dihydrosphingosine-1- 
phosphate [381]. This phenomenom has been observed with p-adrenergic 
receptor where over-expression the Gs linked receptor in NG108-15 cells 
(mouse neuroblastoma and glioma hybrid) results in the constitutive activity 
of AC [382]. However, it is unlikely that this is the case for S1Pi there is no 
constitutive agonist-independent phosphorylation of ERK (Figure 3.16).
Although not significantly high there is detectable basal levels of PKB 
phosphorylation thus the constitutive action of the S1Pi receptor may be 
restricted to specific pathways that are responsible for promotion of survival 
(Figure 4.11).
A role for S I Pi in the receptor tyrosine kinase (RTK) PDGFp-mediated 
activation of ERK has been established, where S1Pi and the PDGF receptor 
form a signalling complex [383, 384]. In a recent study in HEK and aortic 
smooth muscle cells this was confirmed using an inverse agonist of S1Pi 
called SB649146 which disrupted PDGFp activation of ERK [385]. This 
would be expected to attenuate SI Pi-mediated survival. PDGFp receptors 
are expressed in CCL39 cells so it is possible that the S I Pi receptor and 
PDGFp receptor are required to associate to initiate downstream survival 
signals. This could be determined by using a PDGF receptor kinase inhibitor 
of which many are used in anti-cancer therapies, which would block SI Pi 
receptor-induced survival [386]. Another RTK involved in PI 3-kinase/PKB 
mediated cell survival is the insulin-like growth factor (IGF) receptor which 
has recently been linked to transactivation of S IP  receptors. The neutral
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antagonist of the S1Pi and S IP 3 receptors, VPC23019, which has been 
demonstrated to block IGF-stimulated ERK activation would be expected to 
have no effect on the effect on S IP 1-mediated survival [387].
The inhibition of protein synthesis by emetine treatment attenuates 
S IP 1-mediated survival (Figure 4.13). This implicates S IP 1 in the control of 
the expression of one or more anti-apoptotic proteins which may bind and 
sequester pro-apoptotic proteins such as Bim. An anti-apoptotic protein such 
as Mcl-1 which has a short half-life of approximately three hours [388, 389] 
and is known to bind and negate the pro-apoptotic effects of Bim is a good 
candidate. Furthermore, PKB has been implicated in Mcl-1 stability as 
inhibition of its downstream target GSK-3 by inhibitors, resulted increased 
proteosomal degradation of Mcl-1 [390]. In CCL39 cells it has been 
demonstrated that treatment with the PI 3-kinase inhibitor LY294002 causes 
the down-regulation of Mcl-1 in response to serum starvation which results in
Bax activation and apoptosis [391]. However, the up-regulation of Bim due to
■■ttreatment with the MEK inhibitor U0126 (as shown in Figure 4.10), does not 
correspond with an increase in caspase-3 activity. This suggests that actual 
Bim levels do not induce apoptosis in this system, and the increase in 
expression levels of Bim observed, is due to the lack of ERK activity 
mediating its degradation.
The protective effect of S IP 1 in the absence of serum was reversed 
using LY294002 and the broad spectrum-specific PKC inhibitor 
GF109203FX. The use of each of these inhibitors singly did increase 
apoptosis but only when used together did they completely reverse S IP i’s 
protective effect. S IP 1 can be phosphorylated independently of agonist by 
PKC which is associated with loss of the receptor from the cell surface [367].
Therefore, the presence of PKC may be responsible for attenuating S IP 1 
signalling by internalisation. PKC has also been demonstrated to stabilise 
newly formed Mcl-1 by phosphorylation [392]. SI Pi activates eNOS via 
PKB; the subsequent production of NO is presumably responsible for the 
cryoprotective effect of 81 Pi signalling. PKB also promotes survival through 
the phosphorylation and inactivation of the pro-apoptotic protein Bad [209].
As these observations were made in an artificial model system where 
SI Pi was over-expressed it is difficult to put these data in context. However,
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it does provide an excellent basis to explore the mechanisms used in other 
cells types where S1P is an important mediator of survival such as 
endothelial cells, VSMCs and also immune cells such as B and T 
lymphocytes where Mcl-1 expression is required for both development and 
maintenance in mature cells [213, 333, 393]. Experiments in cells with 
endogenous receptor would give more insight into the physiological role of 
S1Pi signal transduction in survival. It would also be interesting to look at 
the effects of cytotoxic drugs such as paclitaxel to determine whether this 
response is confined to apoptosis induced by removal of trophic factors. 
Furthermore, confirmation that CCL39mycS1Pi cells do not undergo the 
phenotypic changes expected from apoptotic cells by annexin V and 
propidium iodide staining and flow cytometry, would also be beneficial.
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Figure 4.1 Control CCL39 Cell Morphology In Response to Serum 
Deprivation
Light micrograph images of control CCL39 cells deprived of serum for 
3,6, 12 and 24 hours. Images were captured using a Zeiss microscope (10 x 
objective lense) and manipulated with Axiovision software.
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Figure 4.2 CCL39mycS1Pi Cell Morphology in Response to Serum 
Deprivation
Light micrographs of CCL39 cells stably transfected with mycS1Pi 
deprived of serum for 3,6, 12 and 24 hours. Images were captured using a 
Zeiss microscope (10 x objective lense) and manipulated with Axiovision 
software.
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Figure 4.3 Serum Deprivation of Control CCL39 cells and 
CCL39mycS1Pi Cells and its Effect on Caspase-3 Cleavage
Detection of cleaved caspase-3 in CCL39 cells and CCL39mycS1Pi 
cells which were deprived of serum for 3, 6 , 12, and 24 hours by western 
blot. Receptor and GAPDH levels were also detected by western blot, p 
values are from a one way AN OVA with a Bonferroni comparisons test, bars 
marked with *** have a p<0.001. This Figure is a representative from three 
experiments.
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Figure 4.4 Colorimetric Determination of Caspase-3 Activity in 
Control CCL39 Cells and CCL39mycS1Pi Cells
Apoptosis was induced by serum deprivation for 16 hours, extracts 
were prepared and analysed as per manufacturer’s instructions. The colour 
change detected is caused by cleavage of chromophore p-nitroanaline (pNA) 
from the labelled substrate DEVD-pNA. A standard curve was constructed 
and from which the activity of each sample determined. The colorimetric 
change was determined by reading the samples at OD405 and the activity 
calculated from the standard curve (see section 4.2).
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Figure 4.5 the Effect of Serum Deprivation of Control CCL39 Cells and 
CCL39mycS1Pi Cells on the Level of Bim Expression
Detection of Bim in CCL39 cells and CGL39mycS1Pi cells which have 
been serum-starved for 3, 6, 12, and 24 hours by western blot. Receptor and 
GAPDH levels were also detected by western blot, p values are from a one 
way AN OVA with a Bonferroni comparisons test, bars marked with *** have a 
p<0.001. This Figure is a representative from three experiments.
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Figure 4.6 The Effect of Agonist Stimulation on Caspase-3 Cleavage 
in Control CCL39 Cells and CCL39mycS1Pi Cells
Detection of caspase-3 cleavage by western blot in CCL39 cells and 
CCL39mycS1Pi cells serum-starved for 16 hours and treated concurrently 
with S IP  (5|aM) or FTY720P (0.1 p,M). Receptor level and GAPDH levels 
were also detected by western blot, p values are from a one way AN OVA 
with a Bonferroni comparisons test, bars marked with *** have a p<0.001. 
This Figure is a representative from three experiments.
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Figure 4.7 The Effect of Agonist Stimulation on Bim Expression in 
Control CCL39 Cells and CCL39mycS1Pi Cells
Detection of Bim of CCL39 cells and CCL39mycS1Pi cells by western 
blot which have been serum-starved for 16 hours treated concurrently with 
S IP  (5pM) or FTY720P (O.ljnM). Receptor levels and GAPDH levels were 
also detected by western blot and this Figure is a representative of three 
experiments.
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Figure 4.8 The Effect of the Sphingosine kinase Inhibitor DHS on 
Caspase-3 Cleavage
Detection of cleaved caspase-3 western blot in both CCL39 cells and 
CCL39mycS1Pi cells which have been serum-starved and treated 
concurrently with the sphingosine kinase inhibitor L-f/?reo-dihydrosphingosine 
(DHS) for 16 hours. Receptor levels and GAPDH levels were also detected 
by western blot and this Figure is representative of three experiments.
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Figure 4.9 The Effect of the Sphingosine kinase Inhibitor DHS on Bim 
Expression
Detection of Bim by western blot in both CCL39 cells and 
CCL39mycS1Pi cells which have been serum-starved and treated 
concurrently with the sphingosine kinase inhibitor L-f/7reo-dihydrosphingosine 
(DHS) for 16 hours. Receptor levels and GAPDH levels were also detected 
by western blot and this Figure is representative of three experiments.
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Figure 4.10 The Effect of Pertussis Toxin and U0126 on Caspase-3 
Cleavage and Bim Expression
Detection of cleaved caspase-3 and Bim levels by western blot in 
CCL39mycS1Pi cells cultured in either complete DMEM or serum-free 
□MEM for 16 hours. These cells were treated concurrently with the inhibitors 
U0126 at a concentration of 10pM and pertussis toxin (PTX) at a 
concentration 100ng/ml. Receptor, GAPDH, phospho-ERK (P-ERK) and 
total ERK levels were also detected by western blot, p values are from a one 
way ANOVA with a Bonferroni comparisons test, bars marked with * have a 
p<0.05. This figure is a representative from three experiments.
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Figure 4.11 The Effect of the Inhibitors LY294002 and GF109203X on 
Caspase-3 Cleavage
Detection of cleaved caspase-3 and phospho-PKB (P-PKB) by 
western blot in both CCL39 cells and CCL39mycS1Pi cells which were 
cultured in either complete DMEM or serum-free DMEM for 16 hours. 
CCL39mycS1Pi cells were treated with either LY294002, GF109203X or 
both inhibitors together. Receptor and GAPDH levels were also detected by 
western blot, p values are from a one way ANOVA with a Bonferroni 
comparisons test, bars marked with *** have a p<0.001. This figure is a 
representative from three experiments.
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Figure 4.12 The Effect of the Inhibitors LY294002 and GF109203X on 
Bim Expression Levels
Detection of Bim and phospho-PKB (P-PKB) by western blot in CCL39 
cells and CCL39mycS1Pi cells which were cultured in either complete 
DMEM or serum-free DMEM for 16 hours. CCL39mycS1Pi cells were 
treated with either LY294002, GF109203X or both inhibitors together. 
Receptor and GAPDH levels were also detected by western blot and this 
Figure is a representative of three experiments.
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Figure 4.13 The Effect of Emetine Treatment on Caspase-3 Cleavage 
and Bim Expression
Detection of cleaved caspase-3 and Bim in control CCL39 cells and 
CCL39mycS1Pi cells were serum-starved for 16 hours and subjected to 
treatment with the inhibitor of protein synthesis, emetine (100|aM) over a time 
course of 1, 2, 4 and 8  hours. Receptor and GAPDH levels were also 
detected by western blot and this Figure is a representative of three 
experiments.
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Chapter 5 
Final Discussion
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Summary
The bioactive lipid S1P has been established as a mediator of growth- 
related mechanisms such as cytoskeletai dynamics, migration and cell 
survival [6 8 ]. S1P is derived from sphingomyelin, which is a constituent of all 
eukaryotic membranes and is manufactured within the cell [77]. S1P and its 
derivatives have been detected in yeast to man and the enzymes controlling 
its production are also conserved [71]. SphK, perhaps the most important of 
these, has long been associated with proliferation and cell survival [78, 83] 
but the mechanism for this was unknown until cell surface receptors for the 
lipid were identified.
S IP  is abundant in activated platelets and once secreted, can mediate 
its effects through binding and activating five related GPCRs termed S IP 1.5
[119]. Extracellular S IP  is mainly found associated with HDLs and is present 
in both serum and plasma [103]. The first cell surface receptor to be 
identified for S1P and the most studied of the receptors is S IP 1, which was 
found to be expressed in abundance on endothelial cells [115]. Treatment 
with S IP  was shown to promote capillary-like structures in endothelial 
cultures suggesting a role in vascular processes such as angiogenesis [76, 
116]. S IP 1 can be modified by phosphorylation by intracellular kinases such 
GRK-2 and PKC which causes the removal of the receptor from the cell 
surface into vesicles [367].
S I P 1 . 3  are ubiquitously expressed and influence cytoskeletai 
dynamics and migration via the differential regulation of small G proteins. 
S IP 1 and S I P 3  activate Rac which results in lamellipodial formation and 
migration whereas S IP 2 inhibits Rac which thereby abolishes lamellipodia 
and migration [213, 216]. The regulation of Rac has importance in 
pathological conditions such as cancer. In a melanoma metastasis model 
use of dominant negative Rac demonstrated a requirement for Rac activation 
in metastasis and invasion [394].
In Chapter 3 it is shown that the use of inhibitors such as colchicine, 
cytochalasin B and pertussis toxin did not have any feedback effect on S IP 1 
receptor regulation. There was no change in levels of S IP 1 phosphorylation 
or internalisation. There was no detectable change in levels of GTP-bound 
Rac or Cdc42. In addition to this, the engagement of integrins which is also
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associated with small G protein activation by culturing cells on fibronectin and 
vitronectin did not induce SIP-mediated Rac or Cdc42 activation. S IP 2 , 
which is known to inhibit Rac was not detected and use of the selective 
agonist FTY720P which activates every S1P receptor except S IP 2 did not 
induce Rac or Cdc42 activation. However, S1P treatment did induce the 
formation of stress fibres which is a Rho-mediated process and inhibitory of 
Rac [162]. It is possible that these cells lack an essential co-factor required 
such as the GEF Tiam-1, since the evidence in Chapter 4 indicates PI 3- 
kinase/PKB pathway, which is well documented to activate Rac, is functional 
in these cells [395]. It would, therefore, be beneficial to repeat these 
experiments in cells where SI Pi is expressed endogenously, such as 
endothelial cells, rather than in a system where the receptor is over­
expressed.
As mentioned previously, S IP  has long been associated with cell 
survival, expression of SphK and subsequent S IP  production protects 
against apoptosis induced by a number of stimuli including the removal of 
trophic factors [92, 328]. S IP 1 has been demonstrated to activate eNOS 
through the PI 3-kinase/PKB pathway and there are several mechanisms 
through which NO mediates its cytoprotective effect (as described in section 
1.6.9). Furthermore, it has been demonstrated in CCL39 cells that 
attachment to the substratum is a requirement for PKB signalling [197].
Regardless of the origin of apoptotic stimuli, each signalling pathway 
converges at the mitochondria and the release of cytochrome c. Removal of 
trophic factors causes the up-regulation of BH3-only proteins such as Bim. 
This promotes cytochrome c release and initiates the caspase cascade, 
which ultimately ends in the dismantlement of the cell [283, 336]. Anti- 
apoptotic Bcl-2 proteins, such as Mcl-1 serve to sequester proapoptotic 
proteins, therefore, it is often the balance between these classes of protein 
that will determine cell fate [396]. Caspase-3 is termed an executioner 
caspase, once activated by cleavage at conserved Asp residues, the cell is 
committed to the apoptotic pathway, thereby making it a good marker for 
apoptotic cells [263]. This was supported by findings in Chapter 4 where 
CCL39 cells subjected to serum deprivation showed elevated levels of
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caspase-3 activity in conjunction with the observed elevation of both Bim and 
caspase-3 levels.
The findings of this thesis indicate that the expression of S1 Pi alone is 
enough to attenuate the observed increase in caspase-3 cleavage and Bim 
levels in CCL39 cells. The presence of agonist is not required to see this 
effect, and inhibition of S1P production does not affect S1Pi-mediated 
cytoprotection. However, it is likely that this constitutive activity is restricted 
to pathways controlling survival as it was not accompanied by ERK 
activation. The protective effect conferred by S1Pi was attenuated by 
inhibiting PI 3-kinase (by LY294002) and PKC (by GF203109X). Each of 
these decreased the level of caspase-3 cleavage but only collectively could 
they inhibit the S1Pi receptor’s effect. There is further evidence of another 
level of regulation in the discovery that increased Bim levels do not equate to 
increased caspase-3 levels. This is compounded by the discovery that 
inhibition of protein synthesis by emetine treatment attenuates S1 Pi- 
mediated protection from serum withdrawal. This suggests that S1Pi is the 
driving force behind the expression of a pro-survival protein which negates 
the pro-apoptotic effects of Bim expression. An anti-apoptotic Bci-2 protein 
such as Mcl-1 seems like a potential candidate as studies in CCL39 cells 
have demonstrated that treatment with the PI 3-kinase inhibitor LY294002 
causes the down-regulation of Mcl-1 in response to serum starvation which 
results In Bax activation and apoptosis [391]. The next step would be to 
determine how over-expression of SI Pi affects Mcl-1 expression.
Although these observations were made in an artificial system, the 
evidence strongly points to a role for 81 Pi signalling in the up-regulation of 
one or more anti-apoptotic mediators. Use of selective inhibitors shows that 
the mechanism by which SI Pi protects against apoptosis induced by serum 
withdrawal requires PI 3-kinase and PKC activation.
S I Pi is an important mediator of growth-related functions of the cell 
and the vasculature as a whole. Understanding the mechanisms by which it 
regulates migration, angiogenesis and apoptosis gives valuable insight into 
treating diseases caused by the dysfunction of these processes such as 
cancer. S1Pi signalling is linked to another important mediator of growth- 
related functions, PDGFR. It Is believed that they form a signalling complex
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and co-operate as co-mitogens and promoters of growth [384]. There are 
many PDGF kinase inhibitors that block abberrant PDGF signalling in 
cancerous cells, these drugs also have potential to prevent restenosis for 
patients that have undergone angioplasty [386]. Local injection of S1Pi 
siRNA has also been demonstrated to reduce tumour growth in vivo [232]. 
Furthermore, the S1P receptor antagonist FTY720 inhibits S1P and VEGF- 
induced angiogenesis and impedes tumour progression in vivo thereby 
highlighting S1P receptor antagonists as potential anti-cancer therapies 
[247]. Recent findings indicate that components of the PI 3-kinase/PKB 
pathway are targets for up-regulation, mutation and translocation more often 
that any other pathway on human cancers making it a prime therapeutic 
target [397]. Cancer is a heterogeneous disease and develops due to the 
erroneous signalling of multiple pathways. Understanding these pathways is 
vital to produce multi-faceted therapies against tumourigenesis.
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